
<html lang="en"     class="pb-page"  data-request-id="ca5a153f-fff0-4d67-94d7-3b7478f77fc8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-12;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b00076;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Neil P.  Grimster" /></meta><meta name="dc.Creator" content="Erica  Anderson" /></meta><meta name="dc.Creator" content="Marat  Alimzhanov" /></meta><meta name="dc.Creator" content="Geraldine  Bebernitz" /></meta><meta name="dc.Creator" content="Kirsten  Bell" /></meta><meta name="dc.Creator" content="Claudio  Chuaqui" /></meta><meta name="dc.Creator" content="Tracy  Deegan" /></meta><meta name="dc.Creator" content="Andrew D.  Ferguson" /></meta><meta name="dc.Creator" content="Thomas  Gero" /></meta><meta name="dc.Creator" content="Andreas  Harsch" /></meta><meta name="dc.Creator" content="Dennis  Huszar" /></meta><meta name="dc.Creator" content="Aarti  Kawatkar" /></meta><meta name="dc.Creator" content="Jason G.  Kettle" /></meta><meta name="dc.Creator" content="Paul  Lyne" /></meta><meta name="dc.Creator" content="Jon A.  Read" /></meta><meta name="dc.Creator" content="Caroline  Rivard Costa" /></meta><meta name="dc.Creator" content="Linette  Ruston" /></meta><meta name="dc.Creator" content="Patricia  Schroeder" /></meta><meta name="dc.Creator" content="Jie  Shi" /></meta><meta name="dc.Creator" content="Qibin  Su" /></meta><meta name="dc.Creator" content="Scott  Throner" /></meta><meta name="dc.Creator" content="Dorin  Toader" /></meta><meta name="dc.Creator" content="Melissa  Vasbinder" /></meta><meta name="dc.Creator" content="Richard  Woessner" /></meta><meta name="dc.Creator" content="Haixia  Wang" /></meta><meta name="dc.Creator" content="Allan  Wu" /></meta><meta name="dc.Creator" content="Minwei  Ye" /></meta><meta name="dc.Creator" content="Weijia  Zheng" /></meta><meta name="dc.Creator" content="Michael  Zinda" /></meta><meta name="dc.Description" content="Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homol..." /></meta><meta name="Description" content="Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homol..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 1, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00076" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00076" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00076" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00076" /></link>
        
    
    

<title>Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00076" /></meta><meta property="og:title" content="Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0013.jpeg" /></meta><meta property="og:description" content="Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homologous members: JAK1–3 and TYK2. The development of small-molecule inhibitors that are selective for a specific family member would represent highly desirable tools for deconvoluting the intricacies of JAK family biology. Herein, we report the discovery of a potent JAK1 inhibitor, 24, which displays ∼1000-fold selectivity over the other highly homologous JAK family members (determined by biochemical assays), while also possessing good selectivity over other kinases (determined by panel screening). Moreover, this compound was demonstrated to be orally bioavailable and possesses acceptable pharmacokinetic parameters. In an in vivo study, the compound was observed to dose dependently modulate the phosphorylation of STAT3 (a downstream marker of JAK1 inhibition)." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homologous members: JAK1–3 and TYK2. The development of small-molecule inhibitors that are selective for a specific family member would represent highly desirable tools for deconvoluting the intricacies of JAK family biology. Herein, we report the discovery of a potent JAK1 inhibitor, 24, which displays ∼1000-fold selectivity over the other highly homologous JAK family members (determined by biochemical assays), while also possessing good selectivity over other kinases (determined by panel screening). Moreover, this compound was demonstrated to be orally bioavailable and possesses acceptable pharmacokinetic parameters. In an in vivo study, the compound was observed to dose dependently modulate the phosphorylation of STAT3 (a downstream marker of JAK1 inhibition)." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0013.jpeg" /></meta><meta name="twitter:title" content="Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00076"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00076">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00076&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00076&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00076&amp;href=/doi/10.1021/acs.jmedchem.8b00076" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5235-5244</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00026" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00085" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Neil P. Grimster</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil P. Grimster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Tel.: ++1 781-839-4175. E-mail: <a href="/cdn-cgi/l/email-protection#056b606c692b62776c68767160774564767177647f606b6066642b666a68"><span class="__cf_email__" data-cfemail="2f414a464301485d46425c5b4a5d6f4e5c5b5d4e554a414a4c4e014c4042">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+P.++Grimster">Neil P. Grimster</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0088-1250" title="Orcid link">http://orcid.org/0000-0003-0088-1250</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erica Anderson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erica Anderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erica++Anderson">Erica Anderson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marat Alimzhanov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marat Alimzhanov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marat++Alimzhanov">Marat Alimzhanov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Geraldine Bebernitz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Geraldine Bebernitz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Geraldine++Bebernitz">Geraldine Bebernitz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kirsten Bell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kirsten Bell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kirsten++Bell">Kirsten Bell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claudio Chuaqui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudio Chuaqui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudio++Chuaqui">Claudio Chuaqui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tracy Deegan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tracy Deegan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tracy++Deegan">Tracy Deegan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew D. Ferguson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew D. Ferguson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+D.++Ferguson">Andrew D. Ferguson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Gero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Gero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Gero">Thomas Gero</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Harsch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Harsch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Cambridge CB2 0RE, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Harsch">Andreas Harsch</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dennis Huszar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis Huszar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Cambridge CB2 0RE, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis++Huszar">Dennis Huszar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aarti Kawatkar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aarti Kawatkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aarti++Kawatkar">Aarti Kawatkar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason G. Kettle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason G. Kettle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Cambridge CB2 0RE, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+G.++Kettle">Jason G. Kettle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Lyne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Lyne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Lyne">Paul Lyne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jon A. Read</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon A. Read</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge CB2 0RE, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon+A.++Read">Jon A. Read</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Caroline Rivard Costa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Caroline Rivard Costa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Caroline++Rivard+Costa">Caroline Rivard Costa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linette Ruston</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linette Ruston</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield SK10 2NA, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linette++Ruston">Linette Ruston</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patricia Schroeder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patricia Schroeder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Schroeder">Patricia Schroeder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Shi">Jie Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qibin Su</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qibin Su</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qibin++Su">Qibin Su</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Throner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Throner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Throner">Scott Throner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dorin Toader</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dorin Toader</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dorin++Toader">Dorin Toader</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6330-5280" title="Orcid link">http://orcid.org/0000-0001-6330-5280</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa Vasbinder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa Vasbinder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa++Vasbinder">Melissa Vasbinder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Woessner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Woessner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Woessner">Richard Woessner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haixia Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haixia Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haixia++Wang">Haixia Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Allan Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Allan Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Allan++Wu">Allan Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minwei Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minwei Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minwei++Ye">Minwei Ye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weijia Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weijia Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weijia++Zheng">Weijia Zheng</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael Zinda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Zinda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Zinda">Michael Zinda</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00076&amp;href=/doi/10.1021%2Facs.jmedchem.8b00076" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5235–5244</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 1, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 January 2018</li><li><span class="item_label"><b>Published</b> online</span>1 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 June 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00076" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00076</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5235%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNeil%2BP.%2BGrimster%252C%2BErica%2BAnderson%252C%2BMarat%2BAlimzhanov%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D12%26contentID%3Dacs.jmedchem.8b00076%26title%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BNovel%2BSeries%2Bof%2BHighly%2BSelective%2BJAK1%2BKinase%2BInhibitors%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5244%26publicationDate%3DJune%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00076"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3235</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00076" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;P. Grimster&quot;},{&quot;first_name&quot;:&quot;Erica&quot;,&quot;last_name&quot;:&quot;Anderson&quot;},{&quot;first_name&quot;:&quot;Marat&quot;,&quot;last_name&quot;:&quot;Alimzhanov&quot;},{&quot;first_name&quot;:&quot;Geraldine&quot;,&quot;last_name&quot;:&quot;Bebernitz&quot;},{&quot;first_name&quot;:&quot;Kirsten&quot;,&quot;last_name&quot;:&quot;Bell&quot;},{&quot;first_name&quot;:&quot;Claudio&quot;,&quot;last_name&quot;:&quot;Chuaqui&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;Deegan&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;D. Ferguson&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Gero&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Harsch&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;Huszar&quot;},{&quot;first_name&quot;:&quot;Aarti&quot;,&quot;last_name&quot;:&quot;Kawatkar&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;G. Kettle&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Lyne&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;A. Read&quot;},{&quot;first_name&quot;:&quot;Caroline&quot;,&quot;last_name&quot;:&quot;Rivard Costa&quot;},{&quot;first_name&quot;:&quot;Linette&quot;,&quot;last_name&quot;:&quot;Ruston&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Schroeder&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Qibin&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Throner&quot;},{&quot;first_name&quot;:&quot;Dorin&quot;,&quot;last_name&quot;:&quot;Toader&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;Vasbinder&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Woessner&quot;},{&quot;first_name&quot;:&quot;Haixia&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Allan&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Minwei&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Weijia&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Zinda&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;5235-5244&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00076&quot;},&quot;abstract&quot;:&quot;Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homologous members: JAK1–3 and TYK2. The development of small-molecule inhibitors that are selective for a specific family member would represent highly desirable tools for deconvoluting the intricacies of JAK family biology. Herein, we report the discovery of a potent JAK1 inhibitor, 24, which displays ∼1000-fold selectivity over the other highly homologous JAK family members (determined by biochemical assays), while also possessing good selectivity over other kinases (determined by panel screening). Moreover, this compound was demonstrated to be orally bioavailable and possesses acceptable pharmacokinetic parameters. In an in vivo study, the compound was observed to dose dependently modulate the phosphorylation of STAT3 (a downstream marker of JAK1 inhibition).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00076&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00076" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00076&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00076" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00076&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00076" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00076&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00076&amp;href=/doi/10.1021/acs.jmedchem.8b00076" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00076" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00076" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00076%26sid%3Dliteratum%253Aachs%26pmid%3D29856615%26genre%3Darticle%26aulast%3DGrimster%26date%3D2018%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2Ba%2BNovel%2BSeries%2Bof%2BHighly%2BSelective%2BJAK1%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D12%26spage%3D5235%26epage%3D5244%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/12" title="Go to Volume 61, Issue 12"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/jmcmar.2018.61.issue-12/20180628/jmcmar.2018.61.issue-12.largecover.jpg" alt="Go to Volume 61, Issue 12"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0013.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homologous members: JAK1–3 and TYK2. The development of small-molecule inhibitors that are selective for a specific family member would represent highly desirable tools for deconvoluting the intricacies of JAK family biology. Herein, we report the discovery of a potent JAK1 inhibitor, 24, which displays ∼1000-fold selectivity over the other highly homologous JAK family members (determined by biochemical assays), while also possessing good selectivity over other kinases (determined by panel screening). Moreover, this compound was demonstrated to be orally bioavailable and possesses acceptable pharmacokinetic parameters. In an in vivo study, the compound was observed to dose dependently modulate the phosphorylation of STAT3 (a downstream marker of JAK1 inhibition).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Janus kinases (JAKs) are critical in cytokine signaling through type I and II receptors and have been linked to both cancer<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and inflammatory diseases.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The JAK family consists of four members: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and there are currently two FDA-approved JAK family inhibitors on the market: tofacitinib (<b>1</b>, a JAK1/3 inhibitor from Pfizer)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> for rheumatoid arthritis and ruxolitinib (<b>2</b>, a selective JAK1/2 inhibitor from Incyte/Novartis)<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> for myelofibrosis (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FDA-approved JAK family inhibitors. <sup>a</sup>Measured in our in-house assays at 5 mM ATP concentration. All values represent the geometric mean of at least two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both compounds display good efficacy in a number of disease areas but have known on-target toxicities, such as increased risk of infection, anemia (platelets, red and white blood cells), hypercholesterolemia, and increased transglutaminases and creatinine levels. As such, second generation inhibitors with increased levels of selectivity for JAK1 are currently under clinical evaluation.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The expectation is that these agents will enable better prognosis upon chronic usage because their selectivity over JAK2 will lead to less severe hematological side effects.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">In oncology, the JAK/STAT pathways have been associated with a wide variety of malignancies upon constitutive activation. This can occur through autocrine and paracrine cytokine production, as well as specific activating mutations on the signaling pathway (e.g., cytokine receptors, JAKs, or STATs). Increased activation of STAT3 via phosphorylation at Y705 (pSTAT3) is reported to be elevated in a wide variety of cancers, including breast, liver, prostate, colorectal, head and neck, esophageal, pancreatic, bladder, and non-small cell lung;<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> it has also been implicated in the pathogenesis of diffuse large B-cell lymphoma<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and nasopharyngeal carcinomas.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Overall, persistent elevated STAT3 activity is present in ∼70% of human tumors<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and has been linked to poorer prognosis in many of these settings.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Moreover, elevation of STAT3 signaling is observed in response to both chemotherapy and treatment with oncogenic signaling pathway inhibitors, for example, EGFR, MAPK, and Akt.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> JAK1 is often the primary kinase that phosphorylates STAT3 and thus drives downstream signaling.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Taken together, these findings suggest that small-molecule inhibition of JAK1 may offer a potential therapeutic approach toward the treatment of these resistance or “escape” mechanisms. The highly complex interplay of the JAK/STAT pathways, however, means that elucidating the precise role of JAK1 in these processes has proved challenging. One approach to address these challenges is through the development of small-molecule inhibitors of JAK1 that display a high degree of selectivity versus that of the other family members.</div><div class="NLM_p last">Herein, we describe the discovery of a highly potent ATP-competitive JAK1 inhibitor. This compound displays remarkable selectivity against the other JAK family members, as well as excellent selectivity against all other kinases tested. A detailed biological and pharmacokinetic evaluation of this compound will also be described.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">2,4-Dichloropyrimidines, differentially substituted at the C-5 position, were reacted with anilines under basic conditions to selectively displace the C-4 chloride. A subsequent acid-catalyzed aniline displacement yielded the desired bisanilino pyrimidines (for an example, see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Example Synthesis of Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHCO<sub>3</sub>, EtOH, 80 °C, 16 h, 63%; (b) <b>S14</b>, HCl, EtOH, 120 °C (microwave), 2 h, 36%.</p></p></figure><div class="NLM_p">To override the inherent C-4 reactivity of the pyrimidine core, formylated anilines were deprotonated with sodium hydride and then reacted with C-2 methysulfone pyrimidines.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A subsequent basic workup cleaved the formyl group and yielded the desired 2-anilino-4-chloropyrimidines. Substitution at the 4-position was carried out under acidic conditions in the case of anilines and basic conditions when alkylamines were used (for an example, see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Example Synthesis of Compound <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, 40 °C, 16 h, 83%; (b) (<i>R</i>)-butan-2-amine, DIPEA, butan-1-ol, 125 °C, 24 h, 69%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR Development</h3><div class="NLM_p">To identify selective JAK1 inhibitors, we first screened a 50 000-membered subset of our compound collection, which was biased toward motifs known to bind the ATP binding site of kinases. Initially, three-point IC<sub>50</sub> values were determined, and approximately 1400 compounds were identified as possessing an IC<sub>50</sub> < 100 nM against JAK1 (<i>K</i><sub>m</sub> ATP concentration, 55 μM). These compounds were subsequently rescreened in a five-point IC<sub>50</sub> format versus JAK1, 2, and 3, at the corresponding <i>K</i><sub>m</sub> ATP concentrations (55, 15, and 3 μM, respectively) in order to identify potent and selective starting points for further optimization. Through these efforts, we identified compound <b>3</b> from our previously described EphB4 program.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Compound <b>3</b> displayed excellent JAK1 biochemical potency, as well as moderate selectivity over the other JAK family members tested (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, we observed that the degree of selectivity toward JAK1 appeared to be, in part, determined by the C-2 aniline, with other bis-2,4-anilinopyrimidines, such as <b>4</b>, showing a preference for JAK2 inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Screening Hits</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0007.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity vs JAK2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>3</b></td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.036</td><td class="colsep0 rowsep0" align="char" char=".">0.464</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.371</td><td class="colsep0 rowsep0" align="char" char="."><0.75</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Measured at <i>K</i><sub>m</sub> ATP concentration. All values represent the geometric mean of at least two independent experiments. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Fold selectivity derived from JAK2/JAK1 enzyme IC<sub>50</sub>. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_p">We believed that both <b>3</b> and <b>4</b> were ATP competitive inhibitors that accessed the same binding mode as previously reported;<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> that is, the C-2 aniline of the pyrimidine was positioned toward the solvent channel. Although the ATP binding sites of JAK1, 2, and 3 are highly homologous, there are key structural differences in this region; notably, the solvent channel in JAK1 is flanked by a positively charged arginine, whereas the analogous residues in JAK2 and 3 are neutral (glutamine and serine, respectively). We hypothesized that the interaction of the methylsulfone of <b>3</b> with the arginine may account for its observed selectivity (JAK1 vs JAK2).</div><div class="NLM_p">To test this hypothesis, we combined the C-2 aniline of <b>3</b> with the C-4 aniline of <b>4</b> and synthesized compound <b>5</b>. Initially, we observed that under our assay conditions (<i>K</i><sub>m</sub> ATP concentration) <b>5</b> maintained JAK1 potency (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Increasing the ATP concentration to a more physiologically relevant level (5 mM) reduced the IC<sub>50</sub> of <b>5</b> to 100 nM versus JAK1 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Utilizing the same high ATP conditions to probe JAK2 and JAK3 activity revealed <b>5</b> to be 139- and >300-fold selective for JAK1 over JAK2 and JAK3, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Moreover, replacing the highly lipophilic 3-chloro-2,4-difluoroaniline group from <b>3</b> with 3-hydroxymethylaniline from <b>4</b> had the effect of significantly lowering log <i>D</i> (3.11 vs 1.75) and thus generating a more favorable starting point to begin medicinal chemistry efforts. Initially, we focused on identifying an optimal C-5 substituent of the pyrimidine ring (<b>5</b>–<b>9</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. C-5 Pyrimidine Substitution</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0008.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center">R substituent</th><th class="colsep0 rowsep0" align="center">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity vs JAK2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>5</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><0.003<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a>/0.100</td><td class="colsep0 rowsep0" align="char" char=".">13.9</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">1.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">0.042</td><td class="colsep0 rowsep0" align="char" char=".">6.41</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">1.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.929</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>310</td><td class="colsep0 rowsep0" align="char" char=".">1.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">CI</td><td class="colsep0 rowsep0" align="left"><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.722</td><td class="colsep0 rowsep0" align="char" char=".">12.6</td><td class="colsep0 rowsep0" align="char" char=".">>240</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left"><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.363</td><td class="colsep0 rowsep0" align="char" char=".">6.54</td><td class="colsep0 rowsep0" align="char" char=".">>120</td><td class="colsep0 rowsep0" align="char" char=".">2.43</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. All values represent the geometric mean of at least two independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Fold selectivity derived from JAK2/JAK1 enzyme IC<sub>50</sub>. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Measured at <i>K</i><sub>m</sub> ATP concentration. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_p">As can been seen in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, increasing the size of the substituent at the C-5 position led to an increase in potency for JAK1. Whereas potency was also increased versus JAK2, selectivity was improved for the 5-Me (<b>7</b>) and 5-Cl (<b>8</b>) substitution. We elected to continue our studies maintaining a constant C-5 methyl group, due to its acceptable balance of potency, selectivity, and lipophilicity.</div><div class="NLM_p">Subsequently, a cocrystal structure of <b>7</b> bound in the kinase domain of JAK1 was obtained (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). As expected, the aminopyrimidine core forms a hydrogen bond donor–acceptor motif with the backbone amides of the hinge region, Phe958 and Leu959, and the 5-Me substituent is positioned proximal to gatekeeper residue, Met956. The N–H of the C-4 aniline appears to interact with Asp1021 via a bridging water molecule, and the hydroxymethyl group forms a hydrogen bond to the amide side chain of Asn1008. In the solvent channel, the <i>N</i>-methylpiperazine base and methylsulfone generate a two-point binding interaction; the base forms a salt bridge with Glu966, and the sulfone forms a bidentate interaction with Arg879, as hypothesized. We believed that these structural features in the solvent channel may account for the observed selectivity of <b>7</b> (JAK1 vs JAK2,3).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structures of <b>7</b> (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ELR">6ELR</a>) bound to the human JAK1 kinase domain. Carbon atoms for compounds are shown in green. The protein backbone cartoon is represented in yellow. Selected atoms for the JAK1 side chains are shown as sticks. Close polar contacts are represented as dotted cyan lines. Refined (2fofc) electron density contoured at 1.0 σ is represented as a wire mesh. Some atoms of the active site covering loop have been removed for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having identified this two-point interaction in the solvent channel, we decided to probe the contributions of the individual components (<i>N</i>-Me piperazine and methylsulfone). To this end, compounds <b>10</b> and <b>11</b> were synthesized (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and screened against JAK1, JAK2, and JAK3. Consistent with our model that both interactions are required for potent and selective JAK1 inhibitors, replacement of the basic nitrogen with an oxygen, <b>10</b>, or removal of the sulfone moiety, <b>11</b>, resulted in a reduction in both potency and selectivity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Probing the Solvent Tail Interactions</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0009.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity vs JAK2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">pSTAT3 EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.929</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>309</td><td class="colsep0 rowsep0" align="left">0.099</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.417</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.055</td><td class="colsep0 rowsep0" align="char" char=".">0.357</td><td class="colsep0 rowsep0" align="char" char=".">20.3</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. All values represent the geometric mean of at least two independent experiments. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Fold selectivity derived from JAK2/JAK1 enzyme IC<sub>50</sub>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Represents cellular mode of action assay measuring inhibition of pSTAT3 in NCI-H1975 cells. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>. ND = not determined.</p></div></div></div><div class="NLM_p">Having generated a potent JAK1 inhibitor, <b>7</b>, we were intrigued to examine whether it would show pathway modulation in a cellular setting. To this end, we developed a mode of action assay in NCI-H1975 cells and were pleased to observe that seven inhibited the phosphorylation of STAT3, a direct substrate of JAK1, with an EC<sub>50</sub> of 99 nM (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>). With a compound in hand capable of modulating the JAK1–STAT3 pathway and an understanding of the structural features that govern selectivity over closely related family members, we turned our attention to its metabolic stability. We noted that <b>7</b> suffered from high in vitro metabolism (human liver microsomes: CL<sub>int</sub> = 59.5 μL/min/mg (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>)) and believed that this may be due to demethylation of the <i>N</i>-Me piperazine base.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In an attempt to address this possible metabolic hotspot, we first synthesized secondary amine <b>12</b>. Although <b>12</b> maintained potency and selectivity in our biochemical assay (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), we observed a large reduction in cellular potency. We attributed this to its poor cellular permeability, a problem that was not alleviated upon steric modulation of the secondary amine’s p<i>K</i><sub>a</sub> through incorporation of flanking <i>cis</i>-methyl groups, <b>13</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Next, we removed the basic center entirely by capping it as an acetamide, <b>14</b>, and somewhat surprisingly observed only a minor drop in potency for JAK1. Unfortunately, <b>14</b> displayed a significant reduction in selectivity over JAK2. Compounds <b>15</b> and <b>16</b> attempted to modulate the basicity of the <i>N</i>-Me piperazine, but introduction of an extra hydrogen bond donor, <b>15</b>, resulted in a substantial disconnect between biochemical and cellular activity, while <b>16</b> lost potency against JAK1. Finally, we introduced a bicyclic base, <b>17</b>, which yielded similar levels of potency (biochemical and cellular) and selectivity to <b>7</b> but was found to be more metabolically stable (human liver microsomes: CL<sub>int</sub> = 7.3 vs 59.5 μL/min/mg, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Base Optimization</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0010.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">pSTAT3 EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i></th><th class="colsep0 rowsep0" align="center">Hu Mics CL<sub>int</sub> (μI/min/mg)</th><th class="colsep0 rowsep0" align="center" char=".">PSA (Å<sup>2</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.929</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.099</td><td class="colsep0 rowsep0" align="char" char=".">1.74</td><td class="colsep0 rowsep0" align="left">59.5</td><td class="colsep0 rowsep0" align="char" char=".">109.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.951</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.496</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">123.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.996</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.325</td><td class="colsep0 rowsep0" align="char" char=".">1.24</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">123.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.347</td><td class="colsep0 rowsep0" align="char" char=".">24.6</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="char" char=".">1.74</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">128.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.817</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="char" char=".">1.29</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">132.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">1.03</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.189</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">118.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>17</b></td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">1.18</td><td class="colsep0 rowsep0" align="char" char=".">>27.9</td><td class="colsep0 rowsep0" align="char" char=".">0.092</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="left">7.32</td><td class="colsep0 rowsep0" align="char" char=".">109.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. All values represent the geometric mean of at least two independent experiments. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Represents cellular mode of action assay measuring inhibition of pSTAT3 in NCI-H1975 cells. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>. ND = not determined.</p></div></div></div><div class="NLM_p">During optimization of the base region, we had observed that small structural changes could result in a disconnect between cellular and biochemical potency, and believed that the compounds’ high polar surface area (PSA, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) reduced their ability to traverse the cell membrane.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> To address this issue, we synthesized <b>18</b>, which contained a difluoromethyl group as an isostere,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> for the highly polar methysulfone (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Pleasingly, despite a reduction in JAK1 biochemical potency, <b>18</b> displayed improved cellular activity (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Unfortunately, this came at the expense of selectivity over other JAK family members. In an attempt to lock the conformation of <b>18</b> at the base of the solvent channel, and thereby rigidify its two-point binding mode, we inserted an <i>ortho</i>-fluorine atom, <b>19</b>. Remarkably, <b>19</b> was found to be completely inactive in our biochemical assay against both JAK2 and JAK3. Unfortunately, the removal of the sulfone motif and the addition of three fluorine atoms resulted in a ∼2 log unit increase in lipophilicity (measured log <i>D</i> of 0.82 (<b>17</b>) vs 2.80 (<b>19</b>)), which we believed may lead to poor overall kinase selectivity. In light of this, we replaced the difluoromethylphenyl group with a more polar pyridine motif, <b>20</b>, which we believed may interact with Arg879 via a bridging water molecule. Pleasingly, <b>20</b> displayed good JAK1 biochemical potency and excellent JAK family selectivity. It should be noted that removal of pyridine nitrogen, <b>21</b>, maintained JAK family selectivity but at the expense of JAK1 potency, providing some evidence for the proposed water-mediated interaction with Arg879, suggesting that the placement of the fluorine atom is key to JAK family selectivity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Sulfone Isosteres</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0011.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">pSTAT3 EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">PSA (Å<sup>2</sup>)</th><th class="colsep0 rowsep0" align="center">A549 Gl<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>17</b></td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">1.18</td><td class="colsep0 rowsep0" align="char" char=".">>27.9</td><td class="colsep0 rowsep0" align="char" char=".">0.092</td><td class="colsep0 rowsep0" align="char" char=".">109.8</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.376</td><td class="colsep0 rowsep0" align="char" char=".">18.1</td><td class="colsep0 rowsep0" align="char" char=".">0.037</td><td class="colsep0 rowsep0" align="char" char=".">73.0</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">0.055</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">73.0</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>20</b></td><td class="colsep0 rowsep0" align="char" char=".">0.040</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.068</td><td class="colsep0 rowsep0" align="char" char=".">83.3</td><td class="colsep0 rowsep0" align="left">0.253</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">0.117</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.101</td><td class="colsep0 rowsep0" align="char" char=".">73.0</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Represents cellular mode of action assay measuring inhibition of pSTAT3 in NCI-H1975 cells.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Represents cellular antiproliferation assay in A549 cells. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>. ND = not determined.</p></div></div></div><div class="NLM_p">Having designed out the sulfone group, while maintaining potency and selectivity for JAK1, we were keen to assess the off-target activity of <b>20</b>. When we evaluated an A549 cellular proliferation assay (a cell line in which <i>JAK1</i> knockdown had no effect on cellular viability or proliferation),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> we noted that <b>20</b> potently inhibited proliferation (GI<sub>50</sub> = 0.253 μM).</div><div class="NLM_p">We believed that to generate a truly unique tool molecule capable of probing JAK1 biology in vivo required further improvement in overall kinase selectivity.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> To this end, we synthesized a diverse library of compounds which varied the C-4 substituent of <b>20</b>, installing both alkyl amines and anilines. These compounds were evaluated for JAK1 biochemical potency and their antiproliferative effects in A549 cells. This exercise revealed several compounds which possessed high levels of JAK1 potency but appeared inactive against our A549 assay (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, boxed compounds).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0005.jpeg" id="GRAPHIC-d135e1677-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plot of JAK1 biochemical potency vs cellular antiproliferation assay in A549 cells. Seven compounds in the black box possess potent JAK1 activity while proving inactive (>10 μM) against A549 proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Of these seven compounds, four contained highly lipophilic anilines, and we thus focused our attention on the remaining three compounds (<b>22</b>–<b>24</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Interestingly, all three were highly homologous, with <b>22</b> and <b>24</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> sharing a common <i>R</i> configuration at the stereogenic center. Further profiling these compounds revealed remarkably similar profiles, as may be expected. Compound <b>24</b>, however, possessed a lower log <i>D</i> (2.26 (<b>24</b>) vs 2.70 (<b>22</b>) and 2.70 (<b>23</b>)), and we therefore elected to examine whether it would make an appropriate in vivo probe molecule.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. C-5 Alkylamine Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0012.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">TYK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">pSTAT3 EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">A549 Gl<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">18.1</td><td class="colsep0 rowsep0" align="char" char=".">24.7</td><td class="colsep0 rowsep0" align="char" char=".">0.050</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">0.029</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.044</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. All values represent the geometric mean of at least two independent experiments.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Represents cellular mode of action assay measuring inhibition of pSTAT3 in NCI-H1975 cells.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Represents cellular antiproliferation assay in A549 cells. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Selectivity Profile</h3><div class="NLM_p last">Having already established that <b>24</b> displayed excellent selectivity against both JAK2 and JAK3, we determined its potency against the final family member, TYK2, under high ATP conditions. Pleasingly, <b>24</b> also showed no activity (>30 μM) against TYK2. With a compound in hand that we were confident had ∼1000-fold selectivity over closely related family members, we were interested in assessing its broader kinase selectivity. As such, we screened it against a panel of 386 kinases at a single concentration (1 μM). The kinome profile of compound <b>24</b> is available as <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a> (Table 8). In line with our in-house data, <b>24</b> displayed 100% inhibition at 1 μM for JAK1, while appearing far less active against JAK2 (31%) and JAK3 (46%). For all other kinases tested, only PRKD1 (73%), NUAK1 (71%), and LRRK2 (71%) displayed >70% inhibition, whereas nine others showed >50% inhibition.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetic Properties of <b>24</b></h3><div class="NLM_p">Having established that <b>24</b> was both a highly potent and selective JAK1 inhibitor, we performed a pharmacokinetic study in mice to evaluate its potential as an in vivo tool compound (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Properties of <b>24</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>obs</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>dss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM·h)</th><th class="colsep0 rowsep0" align="center"><i>F</i>%</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">iv<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">68.7</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">po<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.65</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="left">po<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">18.9</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">10% HPbCD + 5% dextrose in WFI at pH 4.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">5% SBECD in WFI at pH 2. ND = not determined. For experimental details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_p last">Although <b>24</b> displayed moderately high clearance but acceptable bioavailability at lower dose (10 mg/kg), the plasma concentrations reached at the higher oral dose of 50 mg/kg were anticipated to achieve target coverage (free plasma concentration over cellular EC<sub>50</sub>, mouse PPB = 15% free) for ∼12 h. We proceeded to test this theory in an in vivo xenograft model.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>24</b> Demonstrates a Clear Pharmacodynamic Effect in NCI-H1975 Mouse Xenograft Model</h3><div class="NLM_p">As previously discussed, STAT3 is a direct phosphorylation substrate of JAK1 in NCI-H1975 cells. Therefore, we measured pSTAT3 levels in tumors from an NCI-H1975 mouse xenograft model. Single doses of <b>24</b> at 1, 3, 10, 30, 50, and 100 mg/kg were given by oral gavage, and animals were sacrificed at 2 h. An additional 6 h group was added for the 50 mg/kg dose. Interestingly, we observed a dose-dependent decrease in pSTAT3 across the doses examined, which correlated with the plasma concentrations of <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In addition, after 6 h, the 50 mg/kg dose showed a reduction in both the plasma concentration of <b>24</b> as well as suppression of pSTAT3 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0006.jpeg" id="GRAPHIC-d135e2048-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of % inhibition of pSTAT3 in an NCI-H1975 mouse xenograft model and the corresponding plasma concentrations of <b>24</b>. Student’s <i>t</i>-test calculated versus vehicle control; <i>p</i> < 0.05 for doses 100, 50 (2 and 6 h), and 30 mg/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have described the discovery of a highly potent and selective JAK1 ATP competitive inhibitor <b>24</b>, which displays almost 1000-fold selectivity over the highly homologous JAK family members (as determined by high ATP biochemical assays), as well as good selectivity against other kinases tested (as determined by panel screening). Compound <b>24</b> also possesses favorable PK parameters and was demonstrated to be orally efficacious at inhibiting the phosphorylation of STAT3 in tumors in an in vivo model. In the future, we believe that <b>24</b> will prove to be a valuable probe molecule for deconvoluting the intricacies of the JAK family biology.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14053" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14053" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All reactions were performed under inert conditions (nitrogen) unless otherwise stated. Temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18–25 °C. All solvents and reagents were purchased from commercial sources and used without further purification. For coupling reactions, all solvents were dried and degassed prior to reaction. Reactions performed under microwave irradiation utilized either a Biotage Initiator or CEM Discover microwave. Upon workup, organic solvents were typically dried prior to concentration with anhydrous MgSO<sub>4</sub> or Na<sub>2</sub>SO<sub>4</sub>. Flash silica chromatography was typically performed on an Isco Companion, using Silicycle silica gel, 230–400 mesh 40–63 μm cartridges, Grace Resolv silica cartridgesm or Isolute Flash Si or Si II cartridges. Reverse-phase chromatography was performed using a Waters XBridge Prep C18 OBD column (5 μm silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of either water (containing 0.2% NH<sub>4</sub>OH) and acetonitrile or water (containing 0.1% formic acid) and acetonitrile, as eluents. Analytical LC-MS was performed on a Waters 2790 LC with a 996 PDA and 2000 amu ZQ single quadrupole mass spectrometer using a Phenomenex Gemini 50 × 2.1 mm, 5 μm C18 column, or UPLC-MS was performed on a Waters Acquity UPLC and Waters SQD mass spectrometer. UV detection = 210–400 nm, mass spec = ESI with positive/negative switching. The column used was a Waters Acquity HSS T3, 1.8 μm, 2.1 × 30 mm, at a temperature of 30 °C. Flow rate was 1 mL/min using a solvent gradient of 2–98% B over 1.5 min (total runtime with equilibration back to starting conditions = 2 min), where A = 0.1% formic acid in water and B = 0.1% formic acid in acetonitrile. Purities were measured by UV absorption at 254 nm or TIC and are ≥95% unless otherwise stated. NMR spectra were recorded on a Bruker AV300, AV400, and DRX500 spectrometer at 300 or 500 MHz at 303 K unless otherwise indicated. <sup>1</sup>H NMR spectra are reported as chemical shifts in parts per million (ppm) relative to an internal solvent reference. Yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required. Purity of final compounds was assessed by reversed-phase UHPLC with UV diode array detection at 210–400 nM; all tested compounds were >95% purity.</div><div id="sec100" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure: Displacement of C-2 Pyrimidine Chlorides with Anilines</h3><div class="NLM_p">To an alcoholic solution (0.128 mmol) of 5-subsituted (3-((2-chloropyrimidin-4-yl)(methyl)amino)phenyl)methanol (1.2 equiv) in a microwave reaction vessel were added 3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)aniline (1 equiv) and acid (3 equiv) and heated to 80–125 °C in a microwave for 1–2 h. Solvent was evaporated under reduced pressure, and the resultant residue was partitioned between ethyl acetate and saturated aqueous NaHCO<sub>3</sub>. The organic layer was taken, washed with brine, dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified as indicated per the example.</div><div id="sec5_0_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i><sup>4</sup>-(3-Chloro-2,4-difluorophenyl)-<i>N</i><sup>2</sup>-(3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)phenyl)pyrimidine-2,4-diamine (<b>3</b>)</h4><div class="NLM_p last">Scale: 0.56 mmol. Acid: pTSA. Solvent: IPA. Temp: 125 °C. Time: 1 h. Purification column chromatography (silica gel, 0–2% MeOH (1% 7 M NH<sub>3</sub> in MeOH)/DCM). Sample: <b>3</b> as a light brown solid (25 mg, 14%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.14–9.42 (m, 2 H), 8.10 (d, 1 H), 7.91–8.07 (m, 1 H), 7.70 (s, 1 H), 7.56 (s, 1 H), 7.26 (td, 1 H), 6.92 (s, 1 H), 6.37 (d, 1 H), 2.96–3.17 (m, 8 H), 2.35–2.44 (m, 3 H), 2.21 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 509.13.</div></div><div id="sec5_0_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (3-(2-(3,5-Dimorpholinophenylamino)-5-methylpyrimidin-4-ylamino)phenyl)methanol (<b>4</b>)</h4><div class="NLM_p last">Scale: 0.20 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 100 °C. Time: 3 h. Purification: column chromatography (silica gel, 0–2% MeOH (1% 7 M NH<sub>3</sub> in MeOH)/DCM). Sample: <b>4</b> as an off white solid (38 mg, 14%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1 H), 8.22 (s, 1 H), 7.88 (s, 1 H), 7.65 (s, 1 H), 7.55 (s, 1 H), 7.21 (t, 1 H), 6.97 (d, 1 H), 6.84 (s, 2 H), 6.02 (s, 1 H), 5.12 (t, 1 H), 4.46 (d, 2 H), 3.56–3.68 (m, 8 H), 2.83–2.95 (m, 8 H), 2.08 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 477.26.</div></div><div id="sec5_0_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (3-(2-(3-(4-Methylpiperazin-1-yl)-5-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>5</b>)</h4><div class="NLM_p last">Scale: 0.26 mmol. Acid: HCl, 2 M in diethyl ether. Solvent: EtOH. Temp: 80 °C. Time: 2.5 h. Purification: reverse-phase chromatography (25–35% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 4 min). Sample: <b>5</b> as an off-white solid (5 mg, 4%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.31 (br s, 1 H), 9.22 (br s, 1 H), 7.98 (d, 1 H), 7.66–7.90 (m, 2H), 7.62 (s, 1 H), 7.38 (s, 1 H), 7.20 (t, 1 H), 6.73–7.04 (m, 2 H), 6.21 (d, 1 H), 5.08 (br s, 1 H), 4.42 (s, 2 H), 3.07 (m, 7 H), 2.36 (m, 4 H), 2.12 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 469.31.</div></div><div id="sec5_0_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (3-(5-Fluoro-2-(3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>6</b>)</h4><div class="NLM_p last">Scale: 0.48 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 120 °C. Time: 0.5 h. Purification: reverse-phase chromatography (30–60% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>6</b> as an off-white solid (100 mg, 43%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23–9.48 (m, 2 H), 8.16 (d, 1 H), 7.79 (d, 1 H), 7.55–7.73 (m, 3 H), 7.29 (t, 1 H), 7.04 (d, 1 H), 6.94 (s, 1 H), 5.15 (br s, 1 H), 4.50 (s, 2 H), 2.94–3.27 (m, 8 H), 2.40 (m, 3 H), 2.21 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 487.21.</div></div><div id="sec5_0_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (3-(5-Methyl-2-(3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>7</b>)</h4><div class="NLM_p last">Scale: 4.00 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 120 °C. Time: 2 h. Purification: reverse-phase chromatography (20–40% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>7</b> as an off-white solid (0.70 g, 36%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.14 (s, 1 H), 8.29 (s, 1 H), 7.95 (s, 1 H), 7.63–7.81 (m, 3 H), 7.57 (s, 1H), 7.26 (t, 1 H), 6.99 (d, 1 H), 6.89 (s, 1 H), 5.13 (t, 1 H), 4.49 (d, 2 H), 2.95–3.15 (m, 8 H), 2.40 (s, 3 H), 2.21 (s, 3 H), 2.13 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 483.21.</div></div><div id="sec5_0_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (3-(5-Chloro-2-(3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>8</b>)</h4><div class="NLM_p last">Scale: 0.56 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 120 °C. Time: 0.5 h. Purification: reverse-phase chromatography (20–60% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>8</b> as an off-white solid (0.14 g, 51%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.09 (s, 1 H), 8.69 (s, 1 H), 7.89 (s, 2 H), 7.76 (s, 1 H), 7.68 (s, 2 H), 7.27 (t, 1 H), 7.01 (d, 1 H), 6.89 (s, 1 H), 5.11 (t, 1 H), 4.49 (d, 2 H), 3.88 (s, 3 H), 3.03–3.21 (m, 4 H), 2.42 (m, 4 H), 2.22 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 503.13.</div></div><div id="sec5_0_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (3-(5-Bromo-2-(3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>9</b>)</h4><div class="NLM_p last">Scale: 0.37 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 125 °C. Time: 1 h. Purification: reverse-phase chromatography (20–60% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>9</b> as an off-white solid (109 mg, 54%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.44 (s, 1 H) 8.55 (s, 1 H) 8.29 (s, 1 H) 7.55–7.77 (m, 3 H) 7.51 (s, 1H) 7.29 (t, 1 H) 7.07 (d, 1 H) 6.94 (s, 1 H) 4.97–5.29 (m, 1 H) 4.48 (d, 2 H) 2.93–3.14 (m, 8 H) 2.31–2.43(m, 3 H) 2.21 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 548.8.</div></div><div id="sec5_0_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (3-(5-Methyl-2-(3-(methylsulfonyl)-5-morpholinophenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>10</b>)</h4><div class="NLM_p last">Scale: 0.56 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 125 °C. Time: 0.5 h. Purification: column chromatography (silica gel, 0–3% MeOH/DCM). Sample: <b>10</b> as an off-white solid (115 mg, 63%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1 H), 8.31 (s, 1 H), 7.95 (s, 1 H), 7.60–7.80 (m, 3 H), 7.55 (s, 1 H), 7.26 (t, J = 7.82 Hz, 1 H), 7.00 (d, 1 H), 6.89 (s, 1 H), 5.13 (t, 1 H), 4.49 (d, 2 H), 3.53–3.77 (m, 4 H), 3.11 (s, 3 H), 2.87–3.06 (m, 4 H), 2.13 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 470.3.</div></div><div id="sec5_0_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (3-(5-Methyl-2-(3-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>11</b>)</h4><div class="NLM_p last">Scale: 0.34 mmol. Acid: HCl, 2 M in diethyl ether. Solvent: TFE. Temp: 160 °C. Time: 1 h. Purification: reverse-phase chromatography (20–50% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 5 min). Sample: <b>11</b> as an off-white solid (70 mg, 50%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (s, 1 H), 8.22 (s, 1 H), 7.88 (s, 1 H), 7.67 (d, 1 H), 7.59 (s, 1 H), 7.17–7.29 (m, 3 H), 6.94–7.03 (m, 2 H), 6.45 (dd, 1 H), 5.12 (t, 1 H), 4.49 (d, 2 H), 2.91–3.03 (m, 4 H), 2.35–2.42 (m, 4 H), 2.20 (s, 3 H), 2.10 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 403.2.</div></div><div id="sec5_0_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (3-(5-Methyl-2-(3-(methylsulfonyl)-5-(piperazin-1-yl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>12</b>)</h4><div class="NLM_p last">Scale: 0.51 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 110 °C. Time: 1 h. Purification: column chromatography (silica gel, 0–10% MeOH (1% 7 M NH<sub>3</sub> in MeOH)/DCM). Sample: <b>12</b> as an off white solid (38 mg, 14%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.13 (s, 1 H), 8.29 (s, 1 H), 7.95 (d, 1 H), 7.75 (d, 1 H), 7.61–7.72 (m, 2H), 7.57 (s, 1 H), 7.26 (t, 1 H), 7.00 (d, 1 H), 6.87 (d, 1 H), 5.13 (br s, 1 H), 4.49 (s, 2 H), 2.92–3.20 (m, 7 H), 2.65–2.88 (m, 4H), 2.00–2.17 (m, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 509.13.</div></div><div id="sec5_0_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (3-(2-(3-(<i>cis</i>-3,5-Dimethylpiperazin-1-yl)-5-(methylsulfonyl)phenylamino)-5-methylpyrimidin-4-ylamino)phenyl)methanol (<b>13</b>)</h4><div class="NLM_p last">To a suspension of 3-(2-chloro-5-methylpyrimidin-4-ylamino)phenyl)methanol (0.10 g, 0.40 mmol), 3-(<i>cis</i>-3,5-dimethylpiperazin-1-yl)-5-(methylsulfonyl)aniline (113 mg, 0.40 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.39 g, 1.20 mmol) in 1,4-dioxane (2 mL) were added tris(dibenzylideneacetone)dipalladium(0) (37 mg, 0.04 mmol) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (57 mg, 0.12 mmol) and sealed under a nitrogen atmosphere. The resultant reaction mixture was stirred at 100 °C under nitrogen overnight. The reaction mixture was cooled to room temperature, diluted with DCM, and filtered. The filtrate was concentrated to dryness and purified by column chromatography (silica, 0–10% MeOH/DCM) to afford <b>13</b> as an off-white solid (47 mg, 23%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.13 (s, 1 H), 8.27 (br s, 1H), 7.95 (s, 1 H), 7.79 (s, 1 H), 7.71 (s, 1 H), 7.62 (d, 2 H), 7.26 (t, 1 H), 6.99 (d, 1 H), 6.90 (s, 1 H), 5.11 (s, 1 H), 4.49 (d, 2 H), 3.45 (d, 2 H), 3.11 (s, 3 H), 2.71–2.84 (m, 2 H), 2.04–2.17 (m, 5 H), 0.98 (d, J = 6.22 Hz, 6 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 497.26.</div></div><div id="sec5_0_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-(4-(3-(4-(3-(Hydroxymethyl)phenylamino)-5-methylpyrimidin-2-ylamino)-5-(methylsulfonyl)phenyl)piperazin-1-yl)ethanone (<b>14</b>)</h4><div class="NLM_p last">To a suspension of 3-(2-chloro-5-methylpyrimidin-4-ylamino)phenyl)methanol (0.10 mg, 0.40 mmol), 1-(4-(3-amino-5-(methylsulfonyl)phenyl)piperazin-1-yl)ethanone (0.12 mg, 0.40 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.39 g, 1.20 mmol) in 1,4-dioxane (2 mL) were added tris(dibenzylideneacetone)dipalladium(0) (37 mg, 0.04 mmol) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (57 mg, 0.12 mmol) and sealed under a nitrogen atmosphere. The resultant reaction mixture was stirred at 100 °C. The reaction mixture was cooled to room temperature, diluted with DCM, and filtered. The filtrate was concentrated to dryness and purified by column chromatography (silica gel, 0–40% MeOH/DCM) to afford <b>14</b> as a cream-colored solid (0.11 g, 96%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1 H), 8.32 (s, 1 H), 7.95 (s, 1 H), 7.68–7.76 (m, 2 H), 7.65 (s, 1 H), 7.56 (s, 1 H), 7.26 (t, 1 H), 7.00 (d, 1 H), 6.92 (s, 1 H), 5.13 (t, 1 H), 4.49 (d, 2 H), 3.50 (s, 4 H), 3.11 (s, 3 H), 2.97–3.10 (m, 4 H), 2.13 (s, 3 H), 2.04 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 511.08.</div></div><div id="sec5_0_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(4-(3-(4-(3-(Hydroxymethyl)phenylamino)pyrimidin-2-ylamino)-5-(methylsulfonyl)phenyl)piperazin-1-yl)ethanol (<b>15</b>)</h4><div class="NLM_p last">Scale: 0.40 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 80 °C. Time: 2.5 h. Purification: column chromatography (silica gel, 0–10% MeOH/DCM). Sample: <b>15</b> as an off-white solid (12 mg, 6%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.18 (s, 1 H), 8.32 (s, 1 H), 7.95 (s, 1 H), 7.65–7.77 (m, 3 H), 7.56 (s, 1 H), 7.26 (t, 1 H), 7.00 (d, 1 H), 6.87–6.95 (m, 1 H), 5.12–5.21 (m, 1 H), 4.46–4.54 (m, 2 H), 3.52–3.75 (m, 2 H), 2.96–3.26 (m, 8 H), 2.67 (m, J = 2.00 Hz, 2 H), 2.52–2.64 (m, 3 H), 2.12 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 513.18.</div></div><div id="sec5_0_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (3-(2-(3-(4-(2-Methoxyethyl)piperazin-1-yl)-5-(methylsulfonyl)phenylamino)-5-methylpyrimidin-4-ylamino)phenyl)methanol (<b>16</b>)</h4><div class="NLM_p last">Scale: 0.38 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: IPA. Temp: 125 °C. Time: 1 h. Purification: column chromatography (silica gel, 0–3% MeOH/DCM over 35 min). Sample: <b>16</b> as an off-white solid (55 mg, 33%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.89 (s, 1 H), 7.61–7.70 (m, 2 H), 7.48–7.57 (m, 2 H), 7.31 (t, 1 H), 7.10 (d, 1 H), 6.98–7.05 (m, 1 H), 4.59 (s, 2 H), 3.58 (t, 2 H), 3.36 (s, 3 H), 3.07–3.14 (m, 4 H), 3.05 (s, 3 H), 2.62 (dt, 6 H), 2.17 (s, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 527.19.</div></div><div id="sec5_0_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (3-(5-Methyl-2-(3-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-5-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)methanol (<b>17</b>)</h4><div class="NLM_p last">Scale: 0.22 mmol. Acid: HCl, 1.25 M in MeOH. Solvent: EtOH. Temp: 90 °C. Time: 1 h. Purification: column chromatography (silica gel, 0–10% MeOH/DCM). Sample: <b>17</b> as an off-white solid (34 mg, 38%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.01 (s, 1 H), 8.22 (s, 1 H), 7.86 (s, 1 H), 7.64 (d, 1 H), 7.49 (s, 1H), 7.39 (s, 1 H), 7.30 (s, 1 H), 7.19 (t, 1 H), 6.93 (d, 1 H), 6.44 (s, 1 H), 5.13 (br s, 1 H), 4.41 (s, 2 H), 3.94 (br s, 1 H), 3.31 (br s, 1 H), 2.93–3.11 (m, 4 H), 2.63 (d, 1 H), 2.37 (d, 1 H), 2.12–2.24 (m, 3 H), 1.93–2.11 (m, 3 H), 1.53–1.83 (m, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 495.23.</div></div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedure: Displacement of C-4 Anilinopyrimidine Chlorides with Anilines</h3><div class="NLM_p">To a suspension of 4-chloro-pyrimidine (1 equiv) in TFE (0.1 M) were added (3-aminophenyl)methanol (1.1 equiv) and 4 M HCl in 1,4-dioxane (4 equiv) and heated to 150 °C in a microwave for 1 h. The reaction was cooled to room temperature, and solvent was removed under reduced pressure. The residue was purified as indicated per example.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (3-(2-(3-(Difluoromethyl)-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenylamino)-5-methylpyrimidin-4-ylamino)phenyl)methanol (<b>18</b>)</h4><div class="NLM_p last">Scale: 0.1 mmol. Purification: reverse-phase chromatography (40–60% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>18</b> as an off-white solid (25 mg, 51%); <sup>1</sup>H NMR (300 MHz, MeOH-<i>d4</i>) δ 7.87 (s, 1 H) 7.62–7.71 (m, 1 H) 7.45–7.62 (m, 1 H) 7.34 (t, 1 H) 7.15 (dd, 1.70 Hz, 2 H) 6.99 (s, 1 H) 6.51 (s, 1 H) 6.20–6.42 (m, 1 H) 4.60 (s, 2 H) 4.03 (s, 1 H) 3.52 (s, 1 H) 3.12–3.30 (m, 2 H) 2.60–2.85 (m, 2 H) 2.39 (s, 3H) 2.09–2.23 (m, 3 H) 1.63–2.01 (m, 2 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 467.3.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3-(2-(3-(Difluoromethyl)-2-fluoro-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenylamino)-5-methylpyrimidin-4-ylamino)phenyl)methanol (<b>19</b>)</h4><div class="NLM_p last">Scale: 0.1 mmol. Purification: reverse-phase chromatography (30–50% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 5 min). Sample: <b>19</b> as an off-white solid (26 mg, 53%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (d, 2 H), 7.87 (d, J = 0.75 Hz, 1 H), 7.62 (d, 1 H), 7.55 (s, 1 H), 7.19–7.25 (m, 1 H), 7.16 (t, 1 H), 7.06 (t, 1H), 6.95 (d, 1 H), 6.27–6.37 (m, 1 H), 5.15 (br s, 1 H), 4.41 (s, 2 H), 3.95 (s, 1 H), 3.36 (br s, 1 H), 3.10 (d, 1 H), 2.97 (d, 1 H), 2.65 (d, 1 H), 2.37–2.45 (m, 1 H), 2.22 (s, 3 H), 2.09 (s, 3 H), 1.79 (d, 1 H), 1.70 (d, J = 8.85 Hz, 1 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 485.1.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (3-(2-(2-Fluoro-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)phenyl)methanol (<b>20</b>)</h4><div class="NLM_p last">Scale: 0.43 mmol. Purification: reverse-phase chromatography (20–40% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>20</b> as an off-white solid (95 mg, 51%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1 H), 8.23 (s, 1 H), 7.89 (d, 1 H), 7.62 (dd, 1 H), 7.53–7.60 (m, 2 H), 7.19 (t, 1 H), 7.05 (t, 1 H), 6.98 (d, 1 H), 5.14 (t, 1 H), 4.43 (d, 2 H), 3.91 (s, 1 H), 3.27–3.36 (m, 1 H), 3.07 (dd, 1 H), 2.94 (d, 1 H), 2.61 (dd, 1 H), 2.38 (d, 1 H), 2.19 (s, 3 H), 2.09–2.14 (m, 3 H), 1.73–1.81 (m, 1 H), 1.63–1.71 (m, 1 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 436.2.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> General Procedure: Displacement of C-4 Anilinopyrimidine Chlorides with Alkyl Amines</h3><div class="NLM_p">To a suspension of 4-chloro-<i>N</i>-(2-fluoro-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)-5-methylpyrimidin-2-amine (1 equiv) in butan-1-ol (0.25 M) were added alkyl amine (3 equiv) and DIPEA (2 equiv), and the reaction mixture was heated to 125 °C for 24 h. Reaction mixture was evaporated, and the residue was purified as indicated per the example.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i><sup>2</sup>-(2-Fluoro-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)-5-methyl-<i>N</i><sup>4</sup>-(pentan-3-yl)pyrimidine-2,4-diamine (<b>22</b>)</h4><div class="NLM_p last">Scale: 0.43 mmol. Purification: reverse-phase chromatography (40–50% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>22</b> as an off-white solid (0.12 g, 73%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.96 (dd, 1 H), 7.81 (s, 1 H), 7.65 (d, 1 H), 7.01 (t, 1 H), 6.16 (d, 1 H), 4.21 (s, 1 H), 4.03–4.16 (m, 1 H), 3.41 (s, 1 H), 3.30–3.36 (m, 2 H), 2.77 (dd, 1 H), 2.43–2.49 (m, 1 H), 2.24 (s, 3 H), 1.91–1.99 (m, 3 H), 1.87 (d, 1 H), 1.77 (d, 1 H), 1.42–1.63 (m, 4 H), 0.76–0.87 (m, 6 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 400.3.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i><sup>2</sup>-(2-Fluoro-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)-5-methyl-<i>N</i><sup>4</sup>-((<i>R</i>)-3-methylbutan-2-yl)pyrimidine-2,4-diamine (<b>23</b>)</h4><div class="NLM_p last">Scale: 0.43 mmol. Purification: reverse-phase chromatography (40–50% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 10 min). Sample: <b>23</b> as an off-white solid (0.13 g, 76%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91 (dd, 1 H), 7.84 (s, 1 H), 7.65 (d, 1 H), 7.02 (t, 1 H), 6.15 (d, 1 H), 4.22 (s, 1 H), 3.93–4.10 (m, 1 H), 3.41 (s, 1 H), 3.33 (m, 1 H), 3.15 (d, 1 H), 2.77 (dd, 1 H), 2.43–2.49 (m, 1 H), 2.24 (s, 3 H), 1.94 (s, 3 H), 1.72–1.90 (m, 3 H), 1.12 (d, 3 H), 0.87 (dd, 6 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 400.4.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i><sup>2</sup>-(2-Fluoro-5-((1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)-5-methyl-<i>N</i><sup>4</sup>-((<i>R</i>)-butan-2-yl)pyrimidine-2,4-diamine (<b>24</b>)</h4><div class="NLM_p last">Scale: 24.83 mmol. Purification: reverse-phase chromatography (35–50% MeCN/H<sub>2</sub>O 0.2% NH<sub>4</sub>OH, 15 min). Sample: <b>24</b> as a beige crystalline solid (6.63 g, 69%); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.95 (dd, J = 9.06, 2.83 Hz, 1 H), 7.83 (s, 1 H), 7.65 (d, 1 H), 7.01 (t, 1 H), 6.25 (d, 1 H), 4.21 (s, 1 H), 4.09–4.19 (m, 1 H), 3.41 (s, 1 H), 3.29 (m, 1 H), 3.15 (d, 1 H), 2.77 (dd, 1 H), 2.40–2.48 (m, 1 H), 2.24 (s, 3 H), 1.90–1.97 (m, 3 H), 1.87 (d, 1 H), 1.77 (d, 1 H), 1.41–1.66 (m, 2 H), 1.15 (d, 3 H), 0.85 (t, 3 H); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 386.3.</div></div></div><div id="sec200" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Animal Experiments</h3><div class="NLM_p last">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols, which are consistent with The American Chemical Society Publications rules and ethical guidelines.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00076" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00076" class="ext-link">10.1021/acs.jmedchem.8b00076</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Protocols for the enzyme and cell assays, synthetic methods, crystallographic information, and kinase panel selectivity data for compound <b>24</b> in Table 8 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf">jm8b00076_si_001.pdf (1.1 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_002.csv">jm8b00076_si_002.csv (1.79 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00076" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil P. Grimster</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0088-1250" title="Orcid link">http://orcid.org/0000-0003-0088-1250</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6e000b070240091c07031d1a0b1c2e0f1d1a1c0f140b000b0d0f400d0103"><span class="__cf_email__" data-cfemail="503e35393c7e3722393d232435221031232422312a353e3533317e333f3d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erica Anderson</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marat Alimzhanov</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geraldine Bebernitz</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kirsten Bell</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudio Chuaqui</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy Deegan</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew D. Ferguson</span> - <span class="hlFld-Affiliation affiliation">Discovery Sciences, IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Gero</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Harsch</span> - <span class="hlFld-Affiliation affiliation">Oncology, IMED Biotech
Unit and , AstraZeneca, Cambridge CB2 0RE, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis Huszar</span> - <span class="hlFld-Affiliation affiliation">Oncology, IMED Biotech
Unit and , AstraZeneca, Cambridge CB2 0RE, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aarti Kawatkar</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason G. Kettle</span> - <span class="hlFld-Affiliation affiliation">Oncology, IMED Biotech
Unit and , AstraZeneca, Cambridge CB2 0RE, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Lyne</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon A. Read</span> - <span class="hlFld-Affiliation affiliation">Discovery Sciences, IMED Biotech Unit and , AstraZeneca, Cambridge CB2 0RE, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caroline Rivard Costa</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linette Ruston</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield SK10 2NA, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Schroeder</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Shi</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qibin Su</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Throner</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorin Toader</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6330-5280" title="Orcid link">http://orcid.org/0000-0001-6330-5280</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa Vasbinder</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Woessner</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haixia Wang</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allan Wu</span> - <span class="hlFld-Affiliation affiliation">Discovery Sciences, IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minwei Ye</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weijia Zheng</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Zinda</span> - <span class="hlFld-Affiliation affiliation">Oncology,
IMED Biotech Unit and , AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d135e2940-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank A. Hird for proofreading the manuscript and helpful discussions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">EphB4</td><td class="NLM_def"><p class="first last">Ephrin type-B receptor 4</p></td></tr><tr><td class="NLM_term">Phe</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">Leu</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">Met</td><td class="NLM_def"><p class="first last">methionine</p></td></tr><tr><td class="NLM_term">Asp</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">Asn</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term">Glu</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">Arg</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">HPBCD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-beta-cyclodextrin</p></td></tr><tr><td class="NLM_term">wfi</td><td class="NLM_def"><p class="first last">water for injection</p></td></tr><tr><td class="NLM_term">SBECD</td><td class="NLM_def"><p class="first last">sulfobutylether-β-cyclodextrin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 20 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">BCR-ABL1-negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment</span>. <i>Clin Lymphoma Myeloma Leuk</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S37</span>– <span class="NLM_lpage">S45</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.clml.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=22035746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=S37-S45&author=E.+Vakilauthor=A.+Tefferi&title=BCR-ABL1-negative+myeloproliferative+neoplasms%3A+a+review+of+molecular+biology%2C+diagnosis%2C+and+treatment&doi=10.1016%2Fj.clml.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DVakil%26aufirst%3DE.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DBCR-ABL1-negative%2520myeloproliferative%2520neoplasms%253A%2520a%2520review%2520of%2520molecular%2520biology%252C%2520diagnosis%252C%2520and%2520treatment%26jtitle%3DClin%2520Lymphoma%2520Myeloma%2520Leuk%26date%3D2011%26volume%3D11%26spage%3DS37%26epage%3DS45%26doi%3D10.1016%2Fj.clml.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S. E.</span></span> <span> </span><span class="NLM_article-title">Biology and significance of the JAK/STAT signalling pathways</span>. <i>Growth Factors</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.3109/08977194.2012.660936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.3109%2F08977194.2012.660936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=22339650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=88-106&author=H.+Kiuauthor=S.+E.+Nicholson&title=Biology+and+significance+of+the+JAK%2FSTAT+signalling+pathways&doi=10.3109%2F08977194.2012.660936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and significance of the JAK/STAT signalling pathways</span></div><div class="casAuthors">Kiu, Hiu; Nicholson, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-106</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Since its discovery 2 decades ago, the activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway by numerous cytokines and growth factors has resulted in it becoming 1 of the most well-studied intracellular signaling networks.  The field has progressed from the identification of the individual components to high-resoln. crystal structures of both JAK and STAT, and an understanding of the complexities of the mol. activation and deactivation cycle which results in a diverse, yet highly specific and regulated pattern of transcriptional responses.  While there is still more to learn, we now appreciate how disruption and deregulation of this pathway can result in clin. disease and look forward to adoption of the next generation of JAK inhibitors in routine clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2feFVqfQ77Vg90H21EOLACvtfcHk0lhbzImplcocXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D&md5=d81b34c514392de2c2179229633e9a55</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3109%2F08977194.2012.660936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08977194.2012.660936%26sid%3Dliteratum%253Aachs%26aulast%3DKiu%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DS.%2BE.%26atitle%3DBiology%2520and%2520significance%2520of%2520the%2520JAK%252FSTAT%2520signalling%2520pathways%26jtitle%3DGrowth%2520Factors%26date%3D2012%26volume%3D30%26spage%3D88%26epage%3D106%26doi%3D10.3109%2F08977194.2012.660936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: A potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+potent+and+selective+janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljz0nRE8tWusA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson-Viitanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljz0nRE8tWusA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature, part 1</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1080%2F13543776.2017.1252753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=27774824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=127-143&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature%2C+part+1&doi=10.1080%2F13543776.2017.1252753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-143</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 1 covering A through to I.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhs64lbsS9rVg90H21EOLACvtfcHk0lgf5KtTdwX0Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I&md5=90dbe8bc6e86ac19fe512baf6ed82ef7</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252753%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%252C%2520part%25201%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D127%26epage%3D143%26doi%3D10.1080%2F13543776.2017.1252753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature, part 2</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1080%2F13543776.2017.1252754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=27774822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=145-161&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature%2C+part+2&doi=10.1080%2F13543776.2017.1252754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-161</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 2 covering J through Z.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xWVX0ADy67Vg90H21EOLACvtfcHk0lgf5KtTdwX0Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI&md5=c75e5d123fd35306665e0713f801320c</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%252C%2520part%25202%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D145%26epage%3D161%26doi%3D10.1080%2F13543776.2017.1252754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0liOxX6ydx6g5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+Van+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0liOxX6ydx6g5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Ramos, M.</span></span> <span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+Menetauthor=O.+Mammolitiauthor=M.+Lopez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0liOxX6ydx6g5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DLopez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putoczki, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylli, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luwor, R. B.</span></span> <span> </span><span class="NLM_article-title">The role of STAT3 signaling in mediating tumour resistance to cancer therapy</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1353</span>, <span class="refDoi"> DOI: 10.2174/1389450115666141120104146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.2174%2F1389450115666141120104146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=25410411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1341-1353&author=F.+H.+Tanauthor=T.+L.+Putoczkiauthor=S.+S.+Stylliauthor=R.+B.+Luwor&title=The+role+of+STAT3+signaling+in+mediating+tumour+resistance+to+cancer+therapy&doi=10.2174%2F1389450115666141120104146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy</span></div><div class="casAuthors">Tan, Fiona H.; Putoczki, Tracy L.; Stylli, Stanley S.; Luwor, Rodney B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1341-1353</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) is activated in many cancer types and can regulate pathways involving tumorigenesis, cell proliferation, cell survival and angiogenesis.  Upstream cytokine signaling through multiple trans-membrane receptors can enhance the activation of STAT3 and promote tumor progression.  Importantly, STAT3 activation can also be induced via the Janus-activated kinase 1/2 (JAK1/2) and Src family kinases.  Target-specific drug therapies have been developed to inhibit many of the upstream receptor and non-receptor activators of STAT3 and are now approved for clin. use.  Recently, resistance to std.-of-care therapies has been linked to constitutive or unabated STAT3 activation, suggesting that combination therapy with STAT3 inhibitors may be of clin. benefit.  Furthermore, STAT3 activity has also been shown to regulate self-renewal of cancer stem cells that are often refractory to chemotherapy treatment.  This review will focus on STAT3 mediated resistance to cancer therapy and discuss strategies to overcome this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFqm_bChG9_7Vg90H21EOLACvtfcHk0lie0zyOKsdUNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D&md5=fe787b8f33eaa8fd88f4b64fa05913e2</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.2174%2F1389450115666141120104146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450115666141120104146%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DF.%2BH.%26aulast%3DPutoczki%26aufirst%3DT.%2BL.%26aulast%3DStylli%26aufirst%3DS.%2BS.%26aulast%3DLuwor%26aufirst%3DR.%2BB.%26atitle%3DThe%2520role%2520of%2520STAT3%2520signaling%2520in%2520mediating%2520tumour%2520resistance%2520to%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2014%26volume%3D15%26spage%3D1341%26epage%3D1353%26doi%3D10.2174%2F1389450115666141120104146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sansone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the interleukin-6/Jak/Stat pathway in human malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.31.8907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1200%2FJCO.2010.31.8907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=22355058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1005-1014&author=P.+Sansoneauthor=J.+Bromberg&title=Targeting+the+interleukin-6%2FJak%2FStat+pathway+in+human+malignancies&doi=10.1200%2FJCO.2010.31.8907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the interleukin-6/Jak/Stat pathway in human malignancies</span></div><div class="casAuthors">Sansone, Pasquale; Bromberg, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1014</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling.  Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies.  Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6-mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis.  This transcription factor regulates the expression of numerous crit. mediators of tumor formation and metastatic progression.  This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUoiaYph-K7Vg90H21EOLACvtfcHk0lie0zyOKsdUNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D&md5=38fca14c5a694cce722155b32f14c0ae</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.8907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.8907%26sid%3Dliteratum%253Aachs%26aulast%3DSansone%26aufirst%3DP.%26aulast%3DBromberg%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520interleukin-6%252FJak%252FStat%2520pathway%2520in%2520human%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1005%26epage%3D1014%26doi%3D10.1200%2FJCO.2010.31.8907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span> <span> </span><span class="NLM_article-title">Cooperative signaling through the signal transducer and actrivator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">3701</span>– <span class="NLM_lpage">3713</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-09-111948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1182%2Fblood-2007-09-111948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=3701-3713&author=L.+T.+Lamauthor=G.+Wrightauthor=R.+E.+Davis&title=Cooperative+signaling+through+the+signal+transducer+and+actrivator+of+transcription+3+and+nuclear+factor-%CE%BAB+pathways+in+subtypes+of+diffuse+large+B-cell+lymphoma&doi=10.1182%2Fblood-2007-09-111948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-09-111948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-09-111948%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DL.%2BT.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26atitle%3DCooperative%2520signaling%2520through%2520the%2520signal%2520transducer%2520and%2520actrivator%2520of%2520transcription%25203%2520and%2520nuclear%2520factor-%25CE%25BAB%2520pathways%2520in%2520subtypes%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D3701%26epage%3D3713%26doi%3D10.1182%2Fblood-2007-09-111948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span> <span> </span><span class="NLM_article-title">STAT signaling in head and neck cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2489</span>– <span class="NLM_lpage">2495</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1203483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2489-2495&author=J.+I.+Songauthor=J.+R.+Grandis&title=STAT+signaling+in+head+and+neck+cancer&doi=10.1038%2Fsj.onc.1203483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203483%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DJ.%2BI.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DSTAT%2520signaling%2520in%2520head%2520and%2520neck%2520cancer%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2489%26epage%3D2495%26doi%3D10.1038%2Fsj.onc.1203483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STAT proteins: novel molecular targets for cancer drug discovery</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6613</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1204086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11426647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6613-6626&author=J.+Turksonauthor=R.+Jove&title=STAT+proteins%3A+novel+molecular+targets+for+cancer+drug+discovery&doi=10.1038%2Fsj.onc.1204086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">STAT proteins: novel molecular targets for cancer drug discovery</span></div><div class="casAuthors">Turkson, James; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">6613-6626</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 101 refs.  Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors.  Frequently, however, abnormal activity of certain STAT family members, particularly Stat3 and Stat5, is assocd. with a wide variety of human malignancies, including hematol., breast, head and neck, and prostate cancers.  Application of mol. biol. and pharmacol. tools in disease-relevant models has confirmed Stat3 as having a causal role in oncogenesis, and provided validation of Stat3 as a target for cancer drug discovery and therapeutic intervention.  Furthermore, a constitutively-active mutant form of Stat3 is sufficient to induce oncogenic transformation of cells, which form tumors in vivo.  Constitutive activation of Stat3 signaling is accompanied by upregulation of cyclin D1, c-Myc, and Bcl-x, changes consistent with subversion of normal cellular growth and survival control mechanisms.  Block of constitutive Stat3 signaling results in growth inhibition and apoptosis of Stat3-pos. tumor cells in vitro and in vivo.  The obsd. dependence of certain tumors on constitutive Stat3 signaling for growth and survival has wide implications for cancer therapy, offering the potential for preferential tumor cell killing.  This review evaluates constitutive Stat3 activation as a "cancer-causing" factor, and proposes a no. of mol. strategies for targeting Stat3 signaling for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoffTICt_aLhLVg90H21EOLACvtfcHk0lie0zyOKsdUNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D&md5=2011fb621ef70547ddbbef2ed253df98</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204086%26sid%3Dliteratum%253Aachs%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTAT%2520proteins%253A%2520novel%2520molecular%2520targets%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6613%26epage%3D6626%26doi%3D10.1038%2Fsj.onc.1204086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1006/gyno.2000.5931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1006%2Fgyno.2000.5931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11006034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=67-73&author=M.+Huangauthor=C.+Pageauthor=R.+K.+Reynoldsauthor=J.+Lin&title=Constitutive+activation+of+stat+3+oncogene+product+in+human+ovarian+carcinoma+cells&doi=10.1006%2Fgyno.2000.5931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive Activation of Stat 3 Oncogene Product in Human Ovarian Carcinoma Cells</span></div><div class="casAuthors">Huang, Melinda; Page, Carmen; Reynolds, R. Kevin; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Stat 3 functions in transducing signals from the cell's surface to its nucleus and activation of gene transcription.  Aberrations of Stat 3 in breast cancer have raised the possibility of its contribution to oncogenesis.  The goal was to examine ovarian cancer cell lines to det. whether Stat 3 plays a relevant role in ovarian carcinogenesis.  Protein lysates were extd. from normal ovarian surface epithelial cells and malignant cells.  Western blotting techniques were performed with phosphorylation-independent or phosphorylation-specific Stat 3 (Tyr 705) antibody.  Confirmation of Stat 3 activation was detd. by a luciferase reporter driven by a promoter contg. Stat 3-specific binding sites.  Bcl-xL and cyclin D1 were also analyzed by Western blotting.  MDAH 2774, OV-1063, Caov-3, and O.C. 22819 expressed high levels of phosphorylated Stat 3.  In contrast, A2780 and normal ovarian surface epithelial cells had little Stat 3 phosphorylation recognized.  Confirmation of persistent activation of Stat 3 activity was shown by transfection of cells with a Stat 3 luciferase reporter.  Potential downstream mediators of Stat 3 including Bcl-xL and cyclin D1 were also evaluated.  In cells expressing activated Stat 3, high levels of both Bcl-xL and cyclin D1 were detected, whereas in A2780 cells, which did not express activated Stat 3, only low levels of Bcl-xL and cyclin D1 were expressed.Conclusions.  Constitutive activation of Stat 3 is present in ovarian cancer lines but not in normal ovarian surface epithelial cells.  Activation of Stat 3 is a common event during oncogenic transformation upstream to both Bcl-xL and cyclin D1.  The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3pODKA-r__7Vg90H21EOLACvtfcHk0lgjAUAyvNKi2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D&md5=d992c9943608157e112466e3edebfd13</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1006%2Fgyno.2000.5931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgyno.2000.5931%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DR.%2BK.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DConstitutive%2520activation%2520of%2520stat%25203%2520oncogene%2520product%2520in%2520human%2520ovarian%2520carcinoma%2520cells%26jtitle%3DGynecol.%2520Oncol.%26date%3D2000%26volume%3D79%26spage%3D67%26epage%3D73%26doi%3D10.1006%2Fgyno.2000.5931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reintgen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7001</span>– <span class="NLM_lpage">7010</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1205859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=12370822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=7001-7010&author=G.+Niuauthor=T.+Bowmanauthor=M.+Huangauthor=S.+Shiversauthor=D.+Reintgenauthor=A.+Daudauthor=A.+Changauthor=A.+Krakerauthor=R.+Joveauthor=H.+Yu&title=Roles+of+activated+Src+and+Stat3+signaling+in+melanoma+tumor+cell+growth&doi=10.1038%2Fsj.onc.1205859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span></div><div class="casAuthors">Niu, Guilian; Bowman, Tammy; Huang, Mei; Shivers, Steve; Reintgen, Douglas; Daud, Adil; Chang, Alfred; Kraker, Alan; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">7001-7010</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases.  Moreover, a crit. role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers.  However, the oncogenic signaling pathways in melanoma cells remain to be fully defined.  In this study, the authors demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examd.  Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines.  Consistent with a role of Src in the pathogenesis of melanoma, the authors show that c-Src tyrosine kinase is activated in melanoma cell lines.  Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited.  Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the anti-apoptotic genes, Bcl-xL and Mcl-1.  These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO46ilXC4-MLVg90H21EOLACvtfcHk0lgjAUAyvNKi2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D&md5=6d5f9f43c4ee07a1c2534165dd28fede</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205859%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DBowman%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DShivers%26aufirst%3DS.%26aulast%3DReintgen%26aufirst%3DD.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DRoles%2520of%2520activated%2520Src%2520and%2520Stat3%2520signaling%2520in%2520melanoma%2520tumor%2520cell%2520growth%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D7001%26epage%3D7010%26doi%3D10.1038%2Fsj.onc.1205859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span> <span> </span><span class="NLM_article-title">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1016/S0022-5347(05)64741-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2FS0022-5347%2805%2964741-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=12131365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2002&pages=762-765&author=A.+Horiguchiauthor=M.+Oyaauthor=T.+Shimadaauthor=A.+Uchidaauthor=K.+Marumoauthor=M.+Murai&title=Activation+of+signal+transducer+and+activator+of+transcription+3+in+renal+cell+carcinoma%3A+a+study+of+incidence+and+its+association+with+pathological+features+and+clinical+outcome&doi=10.1016%2FS0022-5347%2805%2964741-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span></div><div class="casAuthors">Horiguchi, Akio; Oya, Mototsugu; Shimada, Tetsuya; Uchida, Atsushi; Marumo, Ken; Murai, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-765</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: Signal transducer and activator of transcription 3 (STAT3) is known to have an important role in cytokine and growth factor signaling pathways.  In various types of human malignant tumors STAT3 has been shown to be constitutively activated due to aberrant prodn. of cytokines and growth factors.  The authors examd. the presence of STAT3 activation and its assocn. with pathol. features and clin. outcome in renal cell carcinoma cases.  Materials and Methods: the authors examd. 48 paraffin embedded renal cell carcinoma specimens and corresponding nonneoplastic kidney tissues for the activation status of STAT3 on immunohistochem. using anti-phospho-specific (p)-STAT3 antibody, which recognizes only activated STAT3.  Based on the percent of cells with pos. nuclear staining the activation status of STAT3 was detd. and categorized into 2 groups, including low - less than 10% and high - 90% or more tumor cells pos.  The assocns. of the activation status of STAT3 with pathol. features and clin. outcome were analyzed.  Results: Of 48 tumors 24 (50%) demonstrated high levels of nuclear immunostaining for p-STAT3, while the other 24 (50%) showed low levels.  Adjacent nonneoplastic kidney tissues showed only little immunostaining for p-STAT3.  A significant assocn. of high levels of p-STAT3 with metastasis was obsd.  No significant assocns. of p-STAT3 immunostaining with pathol. stage or grade were obsd.  A high level of p-STAT3 was a significant indicator of a poor prognosis on univariate and multivariate anal.  Conclusions: the authors' results indicate a high frequency of STAT3 activation in renal cell carcinoma, esp. in metastatic disease.  STAT3 activation was an independent prognostic variable in renal cell carcinoma cases.  The authors' results strongly suggest that the activation of STAT3 contributes to the development and progression of renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBk-RaURU1VLVg90H21EOLACvtfcHk0lgjAUAyvNKi2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D&md5=a8e5fe3f02f14b11202b78d40a42945b</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2805%2964741-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252805%252964741-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DOya%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DA.%26aulast%3DMarumo%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DM.%26atitle%3DActivation%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520in%2520renal%2520cell%2520carcinoma%253A%2520a%2520study%2520of%2520incidence%2520and%2520its%2520association%2520with%2520pathological%2520features%2520and%2520clinical%2520outcome%26jtitle%3DJ.%2520Urol.%26date%3D2002%26volume%3D168%26spage%3D762%26epage%3D765%26doi%3D10.1016%2FS0022-5347%2805%2964741-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1205152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11850821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=1038-1047&author=A.+Zamoauthor=R.+Chiarleauthor=R.+Pivaauthor=J.+Howesauthor=Y.+Fanauthor=M.+Chilosiauthor=D.+E.+Levyauthor=G.+Inghirami&title=Anaplastic+lymphoma+kinase+%28ALK%29+activates+Stat3+and+protects+hematopoietic+cells+from+cell+death&doi=10.1038%2Fsj.onc.1205152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span></div><div class="casAuthors">Zamo, Alberto; Chiarle, Roberto; Piva, Roberto; Howes, Jennifer; Fan, Yan; Chilosi, Marco; Levy, David E.; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1038-1047</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in anaplastic large cell lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity.  We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs.  Furthermore, immunohistochem. studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely assocd. with ALK expression.  NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro.  Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK.  To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-xL and its role in cell survival in NPM-ALK pos. cells.  NPM-ALK expression caused enhanced Bcl-xL transcription, largely mediated by Stat3.  Increased expression of Bcl-xL provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase.  These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK pos. tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogI4o98Agys7Vg90H21EOLACvtfcHk0lgZ7JzG7tkLyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D&md5=c7b2e63cc7765563b6d30aa4bda2569f</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205152%26sid%3Dliteratum%253Aachs%26aulast%3DZamo%26aufirst%3DA.%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DHowes%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DChilosi%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520activates%2520Stat3%2520and%2520protects%2520hematopoietic%2520cells%2520from%2520cell%2520death%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D1038%26epage%3D1047%26doi%3D10.1038%2Fsj.onc.1205152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Corvinus, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsareva, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfitzner, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L. a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beug, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhlschläger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbhuber, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, K.</span></span> <span> </span><span class="NLM_article-title">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1593/neo.04571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1593%2Fneo.04571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=16036105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=545-555&author=F.+M.+Corvinusauthor=C.+Orthauthor=R.+Morigglauthor=S.+T.+Tsarevaauthor=S.+Wagnerauthor=E.+B.+Pfitznerauthor=D.+Bausauthor=R.+Kaufmanauthor=L.+a.+Huberauthor=K.+Zatloukalauthor=H.+Beugauthor=P.+%C3%96hlschl%C3%A4gerauthor=A.+Sch%C3%BCtzauthor=K.-J.+Halbhuberauthor=K.+Friedrich&title=Persistent+STAT3+activation+in+colon+cancer+is+associated+with+enhanced+cell+proliferation+and+tumor+growth&doi=10.1593%2Fneo.04571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10fR"><div class="casContent"><span class="casTitleNuber">10f</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span></div><div class="casAuthors">Corvinus, Florian M.; Orth, Carina; Moriggl, Richard; Tsareva, Svetlana A.; Wagner, Stefan; Pfitzner, Edith B.; Baus, Daniela; Kaufmann, Roland; Huber, Lukas A.; Zatloukal, Kurt; Beug, Hartmut; Oehlschlaeger, Peter; Schuetz, Alexander; Halbhuber, Karl-Juergen; Friedrich, Karlheinz</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries.  It has so far been molecularly defined mainly by alterations of the Wnt pathway.  We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC.  Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium.  Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture.  However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation.  STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-neg. variant impaired IL-6-driven proliferation.  Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplNySx1-IGqLVg90H21EOLACvtfcHk0lgZ7JzG7tkLyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D&md5=6d74cb8a99173e589ceee0b54c7bd487</span></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1593%2Fneo.04571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.04571%26sid%3Dliteratum%253Aachs%26aulast%3DCorvinus%26aufirst%3DF.%2BM.%26aulast%3DOrth%26aufirst%3DC.%26aulast%3DMoriggl%26aufirst%3DR.%26aulast%3DTsareva%26aufirst%3DS.%2BT.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DPfitzner%26aufirst%3DE.%2BB.%26aulast%3DBaus%26aufirst%3DD.%26aulast%3DKaufman%26aufirst%3DR.%26aulast%3DHuber%26aufirst%3DL.%2Ba.%26aulast%3DZatloukal%26aufirst%3DK.%26aulast%3DBeug%26aufirst%3DH.%26aulast%3D%25C3%2596hlschl%25C3%25A4ger%26aufirst%3DP.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DA.%26aulast%3DHalbhuber%26aufirst%3DK.-J.%26aulast%3DFriedrich%26aufirst%3DK.%26atitle%3DPersistent%2520STAT3%2520activation%2520in%2520colon%2520cancer%2520is%2520associated%2520with%2520enhanced%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D545%26epage%3D555%26doi%3D10.1593%2Fneo.04571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, Y. L.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1002/path.2041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1002%2Fpath.2041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=16917804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2006&pages=224-233&author=K.+C.+Changauthor=M.+H.+Wuauthor=D.+Jonesauthor=F.+F.+Chenauthor=Y.+L.+Tseng&title=Activation+of+STAT3+in+thymic+epithelial+tumours+correlates+with+tumour+type+and+clinical+behaviour&doi=10.1002%2Fpath.2041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10gR"><div class="casContent"><span class="casTitleNuber">10g</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span></div><div class="casAuthors">Chang, K.-C.; Wu, M.-H.; Jones, D.; Chen, F.-F.; Tseng, Y.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-233</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The STAT3 (signal transducers and activators of transcription 3) signalling pathway plays a pivotal role in oncogenesis and appears essential for postnatal maintenance of thymic architecture and thymocyte survival.  The assocn. of STAT3 activation with thymic epithelial tumors (TETs) and myasthenia gravis (MG) has not been elucidated.  In this study, 118 cases of TET and 25 non-neoplastic thymic tissue samples were evaluated for STAT3 and phospho-STAT3 (pSTAT3) expression immunohistochem.  In addn., 44 normal thymuses of different ages were included for comparison.  It was found that STAT3 activation in thymic epithelial cells (TECs), as evidenced by pSTAT3 expression and/or nuclear STAT3, was present in the majority of non-neoplastic thymuses (88%, 22/25), including those from young children, but not in fetal thymus.  In thymoma (n = 73), activated STAT3 was noted at a significantly higher frequency in the cases of lymphocyte-rich thymoma (ie types AB, B1, and B2, 46%, 23/50) in comparison with lymphocyte-depleted thymoma (types A and B3, 1/23) (p = 0.009).  Thymoma with activated STAT3 tended to present at an earlier stage, show complete resectability and less aggressive behavior, and have a higher correlation with MG than the STAT3-neg./inactive group (p < 0.05).  In contrast, thymic carcinoma with activated STAT3 (14/45, 31%) had significantly higher rates of unresectability, vascular invasion, and regional lymph node metastasis (p < 0.05).  These data provide the first evidence that constitutive STAT3 activation is seen in both benign and neoplastic thymic tissue and is assocd. with the persistence of thymic tissue and the presence of MG.  It is likely to be induced by different factors in thymoma and thymic carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGt8X77mhe7Vg90H21EOLACvtfcHk0ljaDxVHXfN_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI&md5=e3966221dfbda9697a2913b34fa8d1cb</span></div><a href="/servlet/linkout?suffix=cit10g&amp;dbid=16384&amp;doi=10.1002%2Fpath.2041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2041%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DF.%2BF.%26aulast%3DTseng%26aufirst%3DY.%2BL.%26atitle%3DActivation%2520of%2520STAT3%2520in%2520thymic%2520epithelial%2520tumours%2520correlates%2520with%2520tumour%2520type%2520and%2520clinical%2520behaviour%26jtitle%3DJ.%2520Pathol.%26date%3D2006%26volume%3D210%26spage%3D224%26epage%3D233%26doi%3D10.1002%2Fpath.2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 affects melanoma on multiple fronts</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1007/s10555-005-1580-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1007%2Fs10555-005-1580-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=15986140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=315-327&author=M.+Kortylewskiauthor=R.+Joveauthor=H.+Yu&title=Targeting+STAT3+affects+melanoma+on+multiple+fronts&doi=10.1007%2Fs10555-005-1580-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10hR"><div class="casContent"><span class="casTitleNuber">10h</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 affects melanoma on multiple fronts</span></div><div class="casAuthors">Kortylewski, Marcin; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-327</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  As a point of convergence for numerous oncogenic signaling pathways, STAT3 is constitutively-activated at 50 to 90% frequency in diverse human cancers, including melanoma.  A crit. role of STAT3 in tumor cell survival, proliferation, angiogenesis, metastasis and immune evasion has been recently demonstrated.  STAT3 contributes to tumor cell growth by regulating the expression of genes that are involved in cell survival and proliferation.  STAT3 promotes metastasis and angiogenesis by inducing expression of the metastatic gene, MMP-2, and the potent angiogenic gene, VEGF.  STAT3 participates in the regulation of tumor immune evasion by inhibiting expression of proinflammatory mediators while promoting expression of immune-suppressing factors, which in turn activates STAT3 signaling in dendritic cells leading to immune tolerance.  Thus, targeting STAT3 for therapy assaults cancer on multiple fronts.  Many of the studies that defined STAT3's role in oncogenesis were carried out in melanoma cells and tumor models.  In this review, we summarize the key role of STAT3 in cancer in general and melanoma in particular.  With the emergence of small-mol. drugs that directly inhibit STAT3 or the oncogenic signaling pathways upstream of STAT3 in melanoma, a promising novel approach for melanoma therapy is emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVSFnD9ExaqLVg90H21EOLACvtfcHk0ljaDxVHXfN_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D&md5=9c3739bf82951bb2f9da6a08ed08e15a</span></div><a href="/servlet/linkout?suffix=cit10h&amp;dbid=16384&amp;doi=10.1007%2Fs10555-005-1580-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-005-1580-1%26sid%3Dliteratum%253Aachs%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DTargeting%2520STAT3%2520affects%2520melanoma%2520on%2520multiple%2520fronts%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2005%26volume%3D24%26spage%3D315%26epage%3D327%26doi%3D10.1007%2Fs10555-005-1580-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidler, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danson, S. J.</span></span> <span> </span><span class="NLM_article-title">The role fo JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fbjc.2015.233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=26151455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=365-371&author=S.+J.+Thomasauthor=J.+A.+Snowdenauthor=M.+P.+Zeidlerauthor=S.+J.+Danson&title=The+role+fo+JAK%2FSTAT+signalling+in+the+pathogenesis%2C+prognosis+and+treatment+of+solid+tumours&doi=10.1038%2Fbjc.2015.233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumors</span></div><div class="casAuthors">Thomas, S. J.; Snowden, J. A.; Zeidler, M. P.; Danson, S. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-371</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells.  Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed.  The JAK/STAT signalling pathway provides an example of this paradigm in haematol. malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clin. effective JAK2 inhibitors, such as ruxolitinib.  It is now clear that many solid tumors also show activation of JAK/STAT signalling.  In this review, we focus on the role of JAK/STAT signalling in solid tumors, examg. the mol. mechanisms that cause inappropriate pathway activation and their cellular consequences.  We also discuss the degree to which activated JAK/STAT signalling contributes to oncogenesis.  Studies showing the effect of activation of JAK/STAT signalling upon prognosis in several tumor types are summarized.  Finally, we discuss the prospects for treating solid tumors using strategies targeting JAK/STAT signalling, including what can be learned from haematol. malignancies and the extent to which results in solid tumors might be expected to differ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZLyuJNOfIZrVg90H21EOLACvtfcHk0lhbI6rkd1RxIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ&md5=d9c42818af6713ce510fea404982968e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.233%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BJ.%26aulast%3DSnowden%26aufirst%3DJ.%2BA.%26aulast%3DZeidler%26aufirst%3DM.%2BP.%26aulast%3DDanson%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520role%2520fo%2520JAK%252FSTAT%2520signalling%2520in%2520the%2520pathogenesis%252C%2520prognosis%2520and%2520treatment%2520of%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D365%26epage%3D371%26doi%3D10.1038%2Fbjc.2015.233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putoczki, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylli, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luwor, R. B.</span></span> <span> </span><span class="NLM_article-title">The role of STAT3 signaling in mediating tumour resistance to cancer therapy</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1353</span>, <span class="refDoi"> DOI: 10.2174/1389450115666141120104146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.2174%2F1389450115666141120104146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=25410411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1341-1353&author=F.+H.+Tanauthor=T.+L.+Putoczkiauthor=S.+S.+Stylliauthor=R.+B.+Luwor&title=The+role+of+STAT3+signaling+in+mediating+tumour+resistance+to+cancer+therapy&doi=10.2174%2F1389450115666141120104146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy</span></div><div class="casAuthors">Tan, Fiona H.; Putoczki, Tracy L.; Stylli, Stanley S.; Luwor, Rodney B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1341-1353</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) is activated in many cancer types and can regulate pathways involving tumorigenesis, cell proliferation, cell survival and angiogenesis.  Upstream cytokine signaling through multiple trans-membrane receptors can enhance the activation of STAT3 and promote tumor progression.  Importantly, STAT3 activation can also be induced via the Janus-activated kinase 1/2 (JAK1/2) and Src family kinases.  Target-specific drug therapies have been developed to inhibit many of the upstream receptor and non-receptor activators of STAT3 and are now approved for clin. use.  Recently, resistance to std.-of-care therapies has been linked to constitutive or unabated STAT3 activation, suggesting that combination therapy with STAT3 inhibitors may be of clin. benefit.  Furthermore, STAT3 activity has also been shown to regulate self-renewal of cancer stem cells that are often refractory to chemotherapy treatment.  This review will focus on STAT3 mediated resistance to cancer therapy and discuss strategies to overcome this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFqm_bChG9_7Vg90H21EOLACvtfcHk0lhbI6rkd1RxIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D&md5=fe787b8f33eaa8fd88f4b64fa05913e2</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.2174%2F1389450115666141120104146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450115666141120104146%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DF.%2BH.%26aulast%3DPutoczki%26aufirst%3DT.%2BL.%26aulast%3DStylli%26aufirst%3DS.%2BS.%26aulast%3DLuwor%26aufirst%3DR.%2BB.%26atitle%3DThe%2520role%2520of%2520STAT3%2520signaling%2520in%2520mediating%2520tumour%2520resistance%2520to%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2014%26volume%3D15%26spage%3D1341%26epage%3D1353%26doi%3D10.2174%2F1389450115666141120104146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of STAT3 expression and its correlation with chemioresistance of non-small cell lung cancer cells</span>. <i>Acta Histochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.acthis.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.acthis.2011.04.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2012&pages=151-158&author=Z.+Yinauthor=Y.+Zhangauthor=Y.+Liauthor=T.+Lvauthor=J.+Liuauthor=X.+Wang&title=Prognostic+significance+of+STAT3+expression+and+its+correlation+with+chemioresistance+of+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.acthis.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.acthis.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acthis.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DPrognostic%2520significance%2520of%2520STAT3%2520expression%2520and%2520its%2520correlation%2520with%2520chemioresistance%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DActa%2520Histochem.%26date%3D2012%26volume%3D114%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.acthis.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J. F.</span></span> <span> </span><span class="NLM_article-title">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3846</span>– <span class="NLM_lpage">3856</span>, <span class="refDoi"> DOI: 10.1172/JCI31871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1172%2FJCI31871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=18060032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=3846-3856&author=S.+P.+Gaoauthor=K.+G.+Markauthor=K.+Leslieauthor=W.+Paoauthor=N.+Motoiauthor=W.+L.+Geraldauthor=W.+D.+Travisauthor=W.+Bornmannauthor=D.+Veachauthor=B.+Clarksonauthor=J.+F.+Bromberg&title=Mutations+in+the+EGFR+kinase+domain+mediate+STAT3+activation+via+IL-6+production+in+human+lung+adenocarcinomas&doi=10.1172%2FJCI31871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span></div><div class="casAuthors">Gao, Sizhi Paul; Mark, Kavin G.; Leslie, Kenneth; Pao, William; Motoi, Noriko; Gerald, William L.; Travis, William D.; Bornmann, William; Veach, Darren; Clarkson, Bayard; Bromberg, Jacqueline F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3846-3856</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas.  PSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR.  Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis.  Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels.  In addn., redn. of IL-6 levels by RNA interference led to a decrease in tumorigenesis.  Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade.  Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased prodn. and release of IL-6.  Finally, immunohistochem. anal. revealed a pos. correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas.  Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-fCYAz8G9S7Vg90H21EOLACvtfcHk0lhGU3RBclO5EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO&md5=4043bc2cf3aecbfbfb3fbd8bf99d6aef</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1172%2FJCI31871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31871%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%2BP.%26aulast%3DMark%26aufirst%3DK.%2BG.%26aulast%3DLeslie%26aufirst%3DK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DGerald%26aufirst%3DW.%2BL.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DBromberg%26aufirst%3DJ.%2BF.%26atitle%3DMutations%2520in%2520the%2520EGFR%2520kinase%2520domain%2520mediate%2520STAT3%2520activation%2520via%2520IL-6%2520production%2520in%2520human%2520lung%2520adenocarcinomas%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D3846%26epage%3D3856%26doi%3D10.1172%2FJCI31871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">JAK1–STAT1–STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1083/jcb.200703184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1083%2Fjcb.200703184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2007&pages=129-138&author=L.+Sunauthor=K.+Maauthor=H.+Wangauthor=F.+Xiaoauthor=Y.+Gaoauthor=W.+Zhangauthor=K.+Wangauthor=X.+Gaoauthor=N.+Ipauthor=Z.+Wu&title=JAK1%E2%80%93STAT1%E2%80%93STAT3%2C+a+key+pathway+promoting+proliferation+and+preventing+premature+differentiation+of+myoblasts&doi=10.1083%2Fjcb.200703184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200703184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200703184%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DIp%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DJAK1%25E2%2580%2593STAT1%25E2%2580%2593STAT3%252C%2520a%2520key%2520pathway%2520promoting%2520proliferation%2520and%2520preventing%2520premature%2520differentiation%2520of%2520myoblasts%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D179%26spage%3D129%26epage%3D138%26doi%3D10.1083%2Fjcb.200703184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, H.</span>; <span class="NLM_string-name">Kubota, Y.</span>; <span class="NLM_string-name">Sato, T.</span>; <span class="NLM_string-name">Arahira, M.</span></span> Patent Appl. <span class="NLM_patent">EP 694538 1996</span>;  <i>Chem. Abstr.</i> <span class="NLM_year">1996</span>,  <span class="NLM_volume">124</span>,  <span class="NLM_fpage">289562</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=H.+Kanno&author=Y.+Kubota&author=T.+Sato&author=M.+Arahira&title=Chem.+Abstr."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKanno%26aufirst%3DH.%26jtitle%3DChem.%2520Abstr.%26date%3D1996%26volume%3D124%26spage%3D289562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortlock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2008.04.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2776-2780&author=C.+Bardelleauthor=D.+Crossauthor=S.+Davenportauthor=J.+G.+Kettleauthor=E.+J.+Koauthor=A.+G.+Leachauthor=A.+Mortlockauthor=J.+Readauthor=N.+J.+Robertsauthor=P.+Robinsauthor=E.+J.+Williams&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+1%3A+structure-based+design+and+optimization+of+a+series+of+2%2C4-bis-anilinopyrimidines&doi=10.1016%2Fj.bmcl.2008.04.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDavenport%26aufirst%3DS.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMortlock%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DRobins%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25201%253A%2520structure-based%2520design%2520and%2520optimization%2520of%2520a%2520series%2520of%25202%252C4-bis-anilinopyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2776%26epage%3D2780%26doi%3D10.1016%2Fj.bmcl.2008.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortlock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimization of 3,5-bis substituted anilinopyrimidines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5717</span>– <span class="NLM_lpage">5721</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2008.09.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5717-5721&author=C.+Bardelleauthor=D.+Crossauthor=S.+Davenportauthor=J.+G.+Kettleauthor=E.+J.+Koauthor=A.+G.+Leachauthor=A.+Mortlockauthor=J.+Readauthor=N.+J.+Robertsauthor=P.+Robinsauthor=E.+J.+Williams&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+2%3A+structure-based+discovery+and+optimization+of+3%2C5-bis+substituted+anilinopyrimidines&doi=10.1016%2Fj.bmcl.2008.09.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.087%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDavenport%26aufirst%3DS.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMortlock%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DRobins%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25202%253A%2520structure-based%2520discovery%2520and%2520optimization%2520of%25203%252C5-bis%2520substituted%2520anilinopyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5717%26epage%3D5721%26doi%3D10.1016%2Fj.bmcl.2008.09.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van
der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6242</span>– <span class="NLM_lpage">6245</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.08.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2010.08.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6242-6245&author=C.+Bardelleauthor=B.+Barlaamauthor=N.+Brooksauthor=T.+Colemanauthor=D.+Crossauthor=R.+Ducrayauthor=I.+Greenauthor=C.+Lambert-van%0Ader+Bremptauthor=A.+Olivierauthor=J.+Read&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+3%3A+identification+of+non-benzodioxole-based+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.08.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.08.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.08.100%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DBrooks%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25203%253A%2520identification%2520of%2520non-benzodioxole-based%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6242%26epage%3D6245%26doi%3D10.1016%2Fj.bmcl.2010.08.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 4: discovery and optimization of a benzylic alcohol series</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2207</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2011.03.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2207-2211&author=B.+Barlaamauthor=R.+Ducrayauthor=C.+Lambert-van+der+Bremptauthor=P.+Pl%C3%A9author=C.+Bardelleauthor=N.+Brooksauthor=T.+Colemanauthor=D.+Crossauthor=J.+G.+Kettleauthor=J.+Read&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+4%3A+discovery+and+optimization+of+a+benzylic+alcohol+series&doi=10.1016%2Fj.bmcl.2011.03.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DRead%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25204%253A%2520discovery%2520and%2520optimization%2520of%2520a%2520benzylic%2520alcohol%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2207%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2011.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, E. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span> <span> </span><span class="NLM_article-title">Identification of the cytochrome P450 enzymes involved in the <i>N</i>-demethylation of sildenafil</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.2001.00318.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1046%2Fj.1365-2125.2001.00318.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11298070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVOntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2001&pages=239-248&author=R.+Hylandauthor=E.+G.+H.+Roeauthor=B.+C.+Jonesauthor=D.+A.+Smith&title=Identification+of+the+cytochrome+P450+enzymes+involved+in+the+N-demethylation+of+sildenafil&doi=10.1046%2Fj.1365-2125.2001.00318.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil</span></div><div class="casAuthors">Hyland, R.; Roe, E. G. H.; Jones, B. C.; Smith, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-248</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: To characterize the cytochrome P 450 (CYP) enzymes responsible for the N-demethylation of sildenafil to its main metabolite, UK-103 320, to investigate the potential inhibitory effects of sildenafil on CYP enzymes and to evaluate the potential of selected drugs to affect sildenafil metab.  Methods: The metabolic pathways of sildenafil N-demethylation were studied using human liver microsomes, as well as microsomes expressing individual human CYP enzymes.  Further studies to identify the individual enzymes were performed at 2.5 and 250 μM sildenafil, and employed a combination of chem. inhibition, correlation anal., and metab. by expressed recombinant CYP enzymes.  In addn., the effect of sildenafil on the activity of the six major drug metabolizing enzymes was investigated.  Results: Sildenafil conversion was mediated by at least two CYP enzymes, for which the mean kinetic parameters were Km1 = 6(±3 μM), Km2 = 81(±45 μM), Vmax1=22(±9 pmol) and Vmax2=138(±77 pmol) UK-103 320 formed min-1 mg-1.  At 250 μM sildenafil, N-demethylation was primarily mediated through the low-affinity, high-Km enzyme (approx. 83%), while at 2.5 μM there was a greater role for the high-affinity, low-Km enzyme (approx. 61%).  Ketoconazole strongly inhibited metab. at both sildenafil concns. and was the only significant inhibitor at 250 μM sildenafil.  At the lower sildenafil concn., sulfaphenazole and quinidine also inhibited formation of UK-103 320.  Overall, 75% or more of the N-demethylation of sildenafil at any concn. is probably attributable to CYP3A4.  These results were supported by expts. using expressed human CYP enzymes, in which only CYP3A4 and CYP2C9 exhibited substantial sildenafil N-demethylase activity (resp. Km values of 221 μM and 27 μM).  Sildenafil metab. was inhibited by potent CYP3A4 inhibitors which are used clin., but was only a weak inhibitor of drug metabolizing enzymes itself, the strongest inhibition occurring against CYP2C9 (Ki=80 μM).  Conclusions: Evidence is provided for CYP3A4 and to a lesser extent CYP2C9-mediated metab. of sildenafil.  There is the possibility that elevated plasma concns. of sildenafil could occur with coadministration of known inhibitors of CYP2C9 or CYP3A4.  Since peak plasma concns. of clin. doses of sildenafil are only 200 ng ml-1 (∼0.4 μM) it is very unlikely that sildenafil will significantly alter the plasma concn. of other compds. metabolized by cytochrome P 450 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C2TltSf-zbVg90H21EOLACvtfcHk0lhC6P7UjREUNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVOntbo%253D&md5=ec1ef78013414aeba31c102e6e7ffeae</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2001.00318.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2001.00318.x%26sid%3Dliteratum%253Aachs%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DRoe%26aufirst%3DE.%2BG.%2BH.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26atitle%3DIdentification%2520of%2520the%2520cytochrome%2520P450%2520enzymes%2520involved%2520in%2520the%2520N-demethylation%2520of%2520sildenafil%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D51%26spage%3D239%26epage%3D248%26doi%3D10.1046%2Fj.1365-2125.2001.00318.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1023/A:1012188625088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1023%2FA%3A1012188625088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=9165525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=568-571&author=K.+Palmauthor=P.+Stenbergauthor=K.+Luthmanauthor=P.+Artursson&title=Polar+molecular+surface+properties+predict+the+intestinal+absorption+of+drugs+in+humans&doi=10.1023%2FA%3A1012188625088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span></div><div class="casAuthors">Palm, Katrin; Stenberg, Patric; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum</span>)
        </div><div class="casAbstract">A theor. method was devised for prediction of drug absorption after oral administration to humans.  Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated.  The compds. also displayed diversity in physicochem. properties such as lipophilicity, hydrogen bonding potential and mol. size.  The dynamic mol. surface properties of the compds. were calcd., taking into account their 3-dimensional shape and flexibility.  An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar mol. surface area (PSAd) (r2 = 0.94).  The relationship was stronger than those obtained for more established predictors of drug absorption.  Drugs that are completely absorbed (FA > 90%) had a PSAd ≤ 60 Å2 while drugs that are < 10% absorbed had a PSAd ≥ 140 Å2.  PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW66hupHIyLVg90H21EOLACvtfcHk0lhC6P7UjREUNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D&md5=1394f0d1059e7d99ee02be977b92da8b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012188625088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012188625088%26sid%3Dliteratum%253Aachs%26aulast%3DPalm%26aufirst%3DK.%26aulast%3DStenberg%26aufirst%3DP.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DPolar%2520molecular%2520surface%2520properties%2520predict%2520the%2520intestinal%2520absorption%2520of%2520drugs%2520in%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D568%26epage%3D571%26doi%3D10.1023%2FA%3A1012188625088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lhct-eWCihG_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohoon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, T. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silkworth, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labowsky, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozhansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacohen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">452</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1158%2F2159-8290.CD-13-0646" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=452&author=Z.+Zhuauthor=A.+R.+Arefauthor=T.+J.+Cohoonauthor=T.+U.+Barbieauthor=Y.+Imamuraauthor=S.+Yangauthor=S.+E.+Moodyauthor=R.+R.+Shenauthor=A.+C.+Schinzelauthor=T.+C.+Thaiauthor=J.+B.+Reibelauthor=P.+Tamayoauthor=J.+T.+Godfreyauthor=Z.+R.+Qianauthor=A.+N.+Pageauthor=K.+Maciagauthor=E.+M.+Chanauthor=W.+Silkworthauthor=M.+T.+Labowskyauthor=L.+Rozhanskyauthor=J.+P.+Mesirovauthor=W.+E.+Gillandersauthor=S.+Oginoauthor=N.+Hacohenauthor=S.+Gaudetauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=R.+B.+Corcoranauthor=K.-K.+Wongauthor=W.+C.+Hahnauthor=D.+A.+Barbie&title=Inhibition+of+KRAS-driven+tumorigenicity+by+interruption+of+an+autocrine+cytokine+circuit&doi=10.1158%2F2159-8290.CD-13-0646"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0646%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DCohoon%26aufirst%3DT.%2BJ.%26aulast%3DBarbie%26aufirst%3DT.%2BU.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DMoody%26aufirst%3DS.%2BE.%26aulast%3DShen%26aufirst%3DR.%2BR.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DThai%26aufirst%3DT.%2BC.%26aulast%3DReibel%26aufirst%3DJ.%2BB.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DGodfrey%26aufirst%3DJ.%2BT.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DPage%26aufirst%3DA.%2BN.%26aulast%3DMaciag%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DSilkworth%26aufirst%3DW.%26aulast%3DLabowsky%26aufirst%3DM.%2BT.%26aulast%3DRozhansky%26aufirst%3DL.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DGillanders%26aufirst%3DW.%2BE.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DHacohen%26aufirst%3DN.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520KRAS-driven%2520tumorigenicity%2520by%2520interruption%2520of%2520an%2520autocrine%2520cytokine%2520circuit%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D452%26doi%3D10.1158%2F2159-8290.CD-13-0646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span> Data for compound <b>24</b> was
previously disclosed under the name AZ-3:<span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span> <span> </span><span class="NLM_article-title">Highly selective JAK1 kinase inhibitors suppress Y705-mediated STAT3 activation in a wide range of tumor types, with reduced hematological toxicity. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; <b>2013</b> Apr 6–10; Washington, DC. Philadelphia (PA): AACR</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">931</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2013-931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1158%2F1538-7445.AM2013-931" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=931&author=R.+Woessnerauthor=G.+Bebernitzauthor=K.+Bellauthor=R.+Cacceseauthor=N.+Johnsonauthor=J.+Kettleauthor=C.+Rivardauthor=P.+Schroederauthor=Q.+Suauthor=H.+Wangauthor=M.+Yeauthor=W.+Zhengauthor=M.+Zindaauthor=P.+Lyneauthor=M.+Vasbinderauthor=D.+Huszarauthor=C.+Chuaqui&title=Highly+selective+JAK1+kinase+inhibitors+suppress+Y705-mediated+STAT3+activation+in+a+wide+range+of+tumor+types%2C+with+reduced+hematological+toxicity.+Proceedings+of+the+104th+Annual+Meeting+of+the+American+Association+for+Cancer+Research%3B+2013+Apr+6%E2%80%9310%3B+Washington%2C+DC.+Philadelphia+%28PA%29%3A+AACR&doi=10.1158%2F1538-7445.AM2013-931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2013-931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2013-931%26sid%3Dliteratum%253Aachs%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DCaccese%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DKettle%26aufirst%3DJ.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DChuaqui%26aufirst%3DC.%26atitle%3DHighly%2520selective%2520JAK1%2520kinase%2520inhibitors%2520suppress%2520Y705-mediated%2520STAT3%2520activation%2520in%2520a%2520wide%2520range%2520of%2520tumor%2520types%252C%2520with%2520reduced%2520hematological%2520toxicity.%2520Proceedings%2520of%2520the%2520104th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%253B%25202013%2520Apr%25206%25E2%2580%259310%253B%2520Washington%252C%2520DC.%2520Philadelphia%2520%2528PA%2529%253A%2520AACR%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D931%26doi%3D10.1158%2F1538-7445.AM2013-931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e','cit10f','cit10g','cit10h'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. Read, Xianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-Holt, Richard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4517-4527. <a href="https://doi.org/10.1021/acs.jmedchem.9b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525282R%252529-N-%25255B3-%25255B2-%25255B%2525283-Methoxy-1-methyl-pyrazol-4-yl%252529amino%25255Dpyrimidin-4-yl%25255D-1H-indol-7-yl%25255D-2-%2525284-methylpiperazin-1-yl%252529propenamide%252B%252528AZD4205%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B1%252BInhibitor%26aulast%3DSu%26aufirst%3DQibin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22082019%26date%3D28042020%26date%3D16042020%26volume%3D63%26issue%3D9%26spage%3D4517%26epage%3D4527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Kersten, Edmond Fleischer, Josef Kehrein, Christoph Borek, Elmar Jaenicke, Christoph Sotriffer, <span class="NLM_string-name hlFld-ContribAuthor">Ruth Brenk</span>. </span><span class="cited-content_cbyCitation_article-title">How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 2095-2113. <a href="https://doi.org/10.1021/acs.jmedchem.9b00586" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00586%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252BTo%252BDesign%252BSelective%252BLigands%252Bfor%252BHighly%252BConserved%252BBinding%252BSites%25253A%252BA%252BCase%252BStudy%252BUsing%252BN-Myristoyltransferases%252Bas%252Ba%252BModel%252BSystem%26aulast%3DKersten%26aufirst%3DChristian%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D05042019%26date%3D19082019%26volume%3D63%26issue%3D5%26spage%3D2095%26epage%3D2113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Subhash Pithani, Marcus Malmgren, Carl-Johan Aurell, Grigorios Nikitidis, <span class="NLM_string-name hlFld-ContribAuthor">Stig D. Friis</span>. </span><span class="cited-content_cbyCitation_article-title">Biphasic Aqueous Reaction Conditions for Process-Friendly Palladium-Catalyzed C–N Cross-Coupling of Aryl Amines. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (8)
                                     , 1752-1757. <a href="https://doi.org/10.1021/acs.oprd.9b00237" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00237%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DBiphasic%252BAqueous%252BReaction%252BConditions%252Bfor%252BProcess-Friendly%252BPalladium-Catalyzed%252BC%2525E2%252580%252593N%252BCross-Coupling%252Bof%252BAryl%252BAmines%26aulast%3DPithani%26aufirst%3DSubhash%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21052019%26date%3D05072019%26volume%3D23%26issue%3D8%26spage%3D1752%26epage%3D1757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Michael S. Bodnarchuk, Iain A. Cumming, <span class="NLM_string-name hlFld-ContribAuthor">James S. Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (19)
                                     , 8934-8943. <a href="https://doi.org/10.1021/acs.jmedchem.8b01148" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLowering%252BLipophilicity%252Bby%252BAdding%252BCarbon%25253A%252BOne-Carbon%252BBridges%252Bof%252BMorpholines%252Band%252BPiperazines%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23072018%26date%3D20092018%26date%3D06092018%26volume%3D61%26issue%3D19%26spage%3D8934%26epage%3D8943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Shen</span>, <span class="hlFld-ContribAuthor ">Lin  Zhao</span>, <span class="hlFld-ContribAuthor ">Peihao  Chen</span>, <span class="hlFld-ContribAuthor ">Yanqiu  Gong</span>, <span class="hlFld-ContribAuthor ">Dingdong  Liu</span>, <span class="hlFld-ContribAuthor ">Xia  Zhang</span>, <span class="hlFld-ContribAuthor ">Lunzhi  Dai</span>, <span class="hlFld-ContribAuthor ">Qingxiang  Sun</span>, <span class="hlFld-ContribAuthor ">Jizhong  Lou</span>, <span class="hlFld-ContribAuthor ">Zhong  Jin</span>, <span class="hlFld-ContribAuthor ">Baohua  Zhang</span>, <span class="hlFld-ContribAuthor ">Dawen  Niu</span>, <span class="hlFld-ContribAuthor ">Ceshi  Chen</span>, <span class="hlFld-ContribAuthor ">Xiangbing  Qi</span>, <span class="hlFld-ContribAuthor ">Da  Jia</span>. </span><span class="cited-content_cbyCitation_article-title">A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2019,</strong> <em>294 </em>
                                    (46)
                                     , 17471-17486. <a href="https://doi.org/10.1074/jbc.RA119.009801" title="DOI URL">https://doi.org/10.1074/jbc.RA119.009801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.009801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.009801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DA%252Bthiazole-derived%252Boridonin%252Banalogue%252Bexhibits%252Bantitumor%252Bactivity%252Bby%252Bdirectly%252Band%252Ballosterically%252Binhibiting%252BSTAT3%26aulast%3DShen%26aufirst%3DXiaofei%26date%3D2019%26volume%3D294%26issue%3D46%26spage%3D17471%26epage%3D17486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Naomi S.  Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126658. <a href="https://doi.org/10.1016/j.bmcl.2019.126658" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126658%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhaled%252BJanus%252BKinase%252B%252528JAK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Wenjie  Li</span>, <span class="hlFld-ContribAuthor ">Yating  Luo</span>, <span class="hlFld-ContribAuthor ">Tingyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyu  Zhao</span>, <span class="hlFld-ContribAuthor ">TianTian  Qi</span>, <span class="hlFld-ContribAuthor ">Fangling  Xu</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Ma</span>, <span class="hlFld-ContribAuthor ">Huan  Ge</span>, <span class="hlFld-ContribAuthor ">Yingfan  Liang</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin  Liang</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1507-1513. <a href="https://doi.org/10.1016/j.bmcl.2019.04.011" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure-activity%252Brelationship%252Bstudy%252Bof%252Baminopyridine%252Bderivatives%252Bas%252Bnovel%252Binhibitors%252Bof%252BJanus%252Bkinase%252B2%26aulast%3DWang%26aufirst%3DWanqi%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1507%26epage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0013.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FDA-approved JAK family inhibitors. <sup>a</sup>Measured in our in-house assays at 5 mM ATP concentration. All values represent the geometric mean of at least two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Example Synthesis of Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHCO<sub>3</sub>, EtOH, 80 °C, 16 h, 63%; (b) <b>S14</b>, HCl, EtOH, 120 °C (microwave), 2 h, 36%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Example Synthesis of Compound <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, 40 °C, 16 h, 83%; (b) (<i>R</i>)-butan-2-amine, DIPEA, butan-1-ol, 125 °C, 24 h, 69%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structures of <b>7</b> (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ELR">6ELR</a>) bound to the human JAK1 kinase domain. Carbon atoms for compounds are shown in green. The protein backbone cartoon is represented in yellow. Selected atoms for the JAK1 side chains are shown as sticks. Close polar contacts are represented as dotted cyan lines. Refined (2fofc) electron density contoured at 1.0 σ is represented as a wire mesh. Some atoms of the active site covering loop have been removed for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0005.jpeg" id="rightTab-GRAPHIC-d135e1677-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plot of JAK1 biochemical potency vs cellular antiproliferation assay in A549 cells. Seven compounds in the black box possess potent JAK1 activity while proving inactive (>10 μM) against A549 proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/medium/jm-2018-00076f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0006.jpeg" id="rightTab-GRAPHIC-d135e2048-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of % inhibition of pSTAT3 in an NCI-H1975 mouse xenograft model and the corresponding plasma concentrations of <b>24</b>. Student’s <i>t</i>-test calculated versus vehicle control; <i>p</i> < 0.05 for doses 100, 50 (2 and 6 h), and 30 mg/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00076/20180622/images/large/jm-2018-00076f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00076&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 20 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">BCR-ABL1-negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment</span>. <i>Clin Lymphoma Myeloma Leuk</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S37</span>– <span class="NLM_lpage">S45</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.clml.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=22035746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=S37-S45&author=E.+Vakilauthor=A.+Tefferi&title=BCR-ABL1-negative+myeloproliferative+neoplasms%3A+a+review+of+molecular+biology%2C+diagnosis%2C+and+treatment&doi=10.1016%2Fj.clml.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DVakil%26aufirst%3DE.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DBCR-ABL1-negative%2520myeloproliferative%2520neoplasms%253A%2520a%2520review%2520of%2520molecular%2520biology%252C%2520diagnosis%252C%2520and%2520treatment%26jtitle%3DClin%2520Lymphoma%2520Myeloma%2520Leuk%26date%3D2011%26volume%3D11%26spage%3DS37%26epage%3DS45%26doi%3D10.1016%2Fj.clml.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S. E.</span></span> <span> </span><span class="NLM_article-title">Biology and significance of the JAK/STAT signalling pathways</span>. <i>Growth Factors</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.3109/08977194.2012.660936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.3109%2F08977194.2012.660936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=22339650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=88-106&author=H.+Kiuauthor=S.+E.+Nicholson&title=Biology+and+significance+of+the+JAK%2FSTAT+signalling+pathways&doi=10.3109%2F08977194.2012.660936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and significance of the JAK/STAT signalling pathways</span></div><div class="casAuthors">Kiu, Hiu; Nicholson, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-106</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Since its discovery 2 decades ago, the activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway by numerous cytokines and growth factors has resulted in it becoming 1 of the most well-studied intracellular signaling networks.  The field has progressed from the identification of the individual components to high-resoln. crystal structures of both JAK and STAT, and an understanding of the complexities of the mol. activation and deactivation cycle which results in a diverse, yet highly specific and regulated pattern of transcriptional responses.  While there is still more to learn, we now appreciate how disruption and deregulation of this pathway can result in clin. disease and look forward to adoption of the next generation of JAK inhibitors in routine clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2feFVqfQ77Vg90H21EOLACvtfcHk0ljrO_d0iTU1QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D&md5=d81b34c514392de2c2179229633e9a55</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3109%2F08977194.2012.660936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08977194.2012.660936%26sid%3Dliteratum%253Aachs%26aulast%3DKiu%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DS.%2BE.%26atitle%3DBiology%2520and%2520significance%2520of%2520the%2520JAK%252FSTAT%2520signalling%2520pathways%26jtitle%3DGrowth%2520Factors%26date%3D2012%26volume%3D30%26spage%3D88%26epage%3D106%26doi%3D10.3109%2F08977194.2012.660936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: A potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+potent+and+selective+janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljAhGaGZxvurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson-Viitanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0lg4Z-pZUFPifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature, part 1</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1080%2F13543776.2017.1252753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=27774824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=127-143&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature%2C+part+1&doi=10.1080%2F13543776.2017.1252753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-143</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 1 covering A through to I.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhs64lbsS9rVg90H21EOLACvtfcHk0lg4Z-pZUFPifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I&md5=90dbe8bc6e86ac19fe512baf6ed82ef7</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252753%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%252C%2520part%25201%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D127%26epage%3D143%26doi%3D10.1080%2F13543776.2017.1252753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature, part 2</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1080%2F13543776.2017.1252754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=27774822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=145-161&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature%2C+part+2&doi=10.1080%2F13543776.2017.1252754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-161</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 2 covering J through Z.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xWVX0ADy67Vg90H21EOLACvtfcHk0lg4Z-pZUFPifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI&md5=c75e5d123fd35306665e0713f801320c</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%252C%2520part%25202%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D145%26epage%3D161%26doi%3D10.1080%2F13543776.2017.1252754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lgvu7BOzvYcUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+Van+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0liEe9fTU3l6UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Ramos, M.</span></span> <span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+Menetauthor=O.+Mammolitiauthor=M.+Lopez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0liEe9fTU3l6UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DLopez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putoczki, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylli, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luwor, R. B.</span></span> <span> </span><span class="NLM_article-title">The role of STAT3 signaling in mediating tumour resistance to cancer therapy</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1353</span>, <span class="refDoi"> DOI: 10.2174/1389450115666141120104146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.2174%2F1389450115666141120104146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=25410411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1341-1353&author=F.+H.+Tanauthor=T.+L.+Putoczkiauthor=S.+S.+Stylliauthor=R.+B.+Luwor&title=The+role+of+STAT3+signaling+in+mediating+tumour+resistance+to+cancer+therapy&doi=10.2174%2F1389450115666141120104146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy</span></div><div class="casAuthors">Tan, Fiona H.; Putoczki, Tracy L.; Stylli, Stanley S.; Luwor, Rodney B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1341-1353</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) is activated in many cancer types and can regulate pathways involving tumorigenesis, cell proliferation, cell survival and angiogenesis.  Upstream cytokine signaling through multiple trans-membrane receptors can enhance the activation of STAT3 and promote tumor progression.  Importantly, STAT3 activation can also be induced via the Janus-activated kinase 1/2 (JAK1/2) and Src family kinases.  Target-specific drug therapies have been developed to inhibit many of the upstream receptor and non-receptor activators of STAT3 and are now approved for clin. use.  Recently, resistance to std.-of-care therapies has been linked to constitutive or unabated STAT3 activation, suggesting that combination therapy with STAT3 inhibitors may be of clin. benefit.  Furthermore, STAT3 activity has also been shown to regulate self-renewal of cancer stem cells that are often refractory to chemotherapy treatment.  This review will focus on STAT3 mediated resistance to cancer therapy and discuss strategies to overcome this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFqm_bChG9_7Vg90H21EOLACvtfcHk0liEe9fTU3l6UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D&md5=fe787b8f33eaa8fd88f4b64fa05913e2</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.2174%2F1389450115666141120104146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450115666141120104146%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DF.%2BH.%26aulast%3DPutoczki%26aufirst%3DT.%2BL.%26aulast%3DStylli%26aufirst%3DS.%2BS.%26aulast%3DLuwor%26aufirst%3DR.%2BB.%26atitle%3DThe%2520role%2520of%2520STAT3%2520signaling%2520in%2520mediating%2520tumour%2520resistance%2520to%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2014%26volume%3D15%26spage%3D1341%26epage%3D1353%26doi%3D10.2174%2F1389450115666141120104146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sansone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the interleukin-6/Jak/Stat pathway in human malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.31.8907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1200%2FJCO.2010.31.8907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=22355058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1005-1014&author=P.+Sansoneauthor=J.+Bromberg&title=Targeting+the+interleukin-6%2FJak%2FStat+pathway+in+human+malignancies&doi=10.1200%2FJCO.2010.31.8907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the interleukin-6/Jak/Stat pathway in human malignancies</span></div><div class="casAuthors">Sansone, Pasquale; Bromberg, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1014</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling.  Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies.  Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6-mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis.  This transcription factor regulates the expression of numerous crit. mediators of tumor formation and metastatic progression.  This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUoiaYph-K7Vg90H21EOLACvtfcHk0lj9mbCj8FDvCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D&md5=38fca14c5a694cce722155b32f14c0ae</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.8907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.8907%26sid%3Dliteratum%253Aachs%26aulast%3DSansone%26aufirst%3DP.%26aulast%3DBromberg%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520interleukin-6%252FJak%252FStat%2520pathway%2520in%2520human%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1005%26epage%3D1014%26doi%3D10.1200%2FJCO.2010.31.8907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span> <span> </span><span class="NLM_article-title">Cooperative signaling through the signal transducer and actrivator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">3701</span>– <span class="NLM_lpage">3713</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-09-111948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1182%2Fblood-2007-09-111948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=3701-3713&author=L.+T.+Lamauthor=G.+Wrightauthor=R.+E.+Davis&title=Cooperative+signaling+through+the+signal+transducer+and+actrivator+of+transcription+3+and+nuclear+factor-%CE%BAB+pathways+in+subtypes+of+diffuse+large+B-cell+lymphoma&doi=10.1182%2Fblood-2007-09-111948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-09-111948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-09-111948%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DL.%2BT.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26atitle%3DCooperative%2520signaling%2520through%2520the%2520signal%2520transducer%2520and%2520actrivator%2520of%2520transcription%25203%2520and%2520nuclear%2520factor-%25CE%25BAB%2520pathways%2520in%2520subtypes%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D3701%26epage%3D3713%26doi%3D10.1182%2Fblood-2007-09-111948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span> <span> </span><span class="NLM_article-title">STAT signaling in head and neck cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2489</span>– <span class="NLM_lpage">2495</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1203483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2489-2495&author=J.+I.+Songauthor=J.+R.+Grandis&title=STAT+signaling+in+head+and+neck+cancer&doi=10.1038%2Fsj.onc.1203483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203483%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DJ.%2BI.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DSTAT%2520signaling%2520in%2520head%2520and%2520neck%2520cancer%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2489%26epage%3D2495%26doi%3D10.1038%2Fsj.onc.1203483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STAT proteins: novel molecular targets for cancer drug discovery</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6613</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1204086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11426647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6613-6626&author=J.+Turksonauthor=R.+Jove&title=STAT+proteins%3A+novel+molecular+targets+for+cancer+drug+discovery&doi=10.1038%2Fsj.onc.1204086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">STAT proteins: novel molecular targets for cancer drug discovery</span></div><div class="casAuthors">Turkson, James; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">6613-6626</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 101 refs.  Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors.  Frequently, however, abnormal activity of certain STAT family members, particularly Stat3 and Stat5, is assocd. with a wide variety of human malignancies, including hematol., breast, head and neck, and prostate cancers.  Application of mol. biol. and pharmacol. tools in disease-relevant models has confirmed Stat3 as having a causal role in oncogenesis, and provided validation of Stat3 as a target for cancer drug discovery and therapeutic intervention.  Furthermore, a constitutively-active mutant form of Stat3 is sufficient to induce oncogenic transformation of cells, which form tumors in vivo.  Constitutive activation of Stat3 signaling is accompanied by upregulation of cyclin D1, c-Myc, and Bcl-x, changes consistent with subversion of normal cellular growth and survival control mechanisms.  Block of constitutive Stat3 signaling results in growth inhibition and apoptosis of Stat3-pos. tumor cells in vitro and in vivo.  The obsd. dependence of certain tumors on constitutive Stat3 signaling for growth and survival has wide implications for cancer therapy, offering the potential for preferential tumor cell killing.  This review evaluates constitutive Stat3 activation as a "cancer-causing" factor, and proposes a no. of mol. strategies for targeting Stat3 signaling for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoffTICt_aLhLVg90H21EOLACvtfcHk0lj9mbCj8FDvCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D&md5=2011fb621ef70547ddbbef2ed253df98</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204086%26sid%3Dliteratum%253Aachs%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTAT%2520proteins%253A%2520novel%2520molecular%2520targets%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6613%26epage%3D6626%26doi%3D10.1038%2Fsj.onc.1204086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1006/gyno.2000.5931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1006%2Fgyno.2000.5931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11006034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=67-73&author=M.+Huangauthor=C.+Pageauthor=R.+K.+Reynoldsauthor=J.+Lin&title=Constitutive+activation+of+stat+3+oncogene+product+in+human+ovarian+carcinoma+cells&doi=10.1006%2Fgyno.2000.5931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive Activation of Stat 3 Oncogene Product in Human Ovarian Carcinoma Cells</span></div><div class="casAuthors">Huang, Melinda; Page, Carmen; Reynolds, R. Kevin; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Stat 3 functions in transducing signals from the cell's surface to its nucleus and activation of gene transcription.  Aberrations of Stat 3 in breast cancer have raised the possibility of its contribution to oncogenesis.  The goal was to examine ovarian cancer cell lines to det. whether Stat 3 plays a relevant role in ovarian carcinogenesis.  Protein lysates were extd. from normal ovarian surface epithelial cells and malignant cells.  Western blotting techniques were performed with phosphorylation-independent or phosphorylation-specific Stat 3 (Tyr 705) antibody.  Confirmation of Stat 3 activation was detd. by a luciferase reporter driven by a promoter contg. Stat 3-specific binding sites.  Bcl-xL and cyclin D1 were also analyzed by Western blotting.  MDAH 2774, OV-1063, Caov-3, and O.C. 22819 expressed high levels of phosphorylated Stat 3.  In contrast, A2780 and normal ovarian surface epithelial cells had little Stat 3 phosphorylation recognized.  Confirmation of persistent activation of Stat 3 activity was shown by transfection of cells with a Stat 3 luciferase reporter.  Potential downstream mediators of Stat 3 including Bcl-xL and cyclin D1 were also evaluated.  In cells expressing activated Stat 3, high levels of both Bcl-xL and cyclin D1 were detected, whereas in A2780 cells, which did not express activated Stat 3, only low levels of Bcl-xL and cyclin D1 were expressed.Conclusions.  Constitutive activation of Stat 3 is present in ovarian cancer lines but not in normal ovarian surface epithelial cells.  Activation of Stat 3 is a common event during oncogenic transformation upstream to both Bcl-xL and cyclin D1.  The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3pODKA-r__7Vg90H21EOLACvtfcHk0lj9mbCj8FDvCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D&md5=d992c9943608157e112466e3edebfd13</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1006%2Fgyno.2000.5931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgyno.2000.5931%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DR.%2BK.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DConstitutive%2520activation%2520of%2520stat%25203%2520oncogene%2520product%2520in%2520human%2520ovarian%2520carcinoma%2520cells%26jtitle%3DGynecol.%2520Oncol.%26date%3D2000%26volume%3D79%26spage%3D67%26epage%3D73%26doi%3D10.1006%2Fgyno.2000.5931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reintgen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7001</span>– <span class="NLM_lpage">7010</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1205859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=12370822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=7001-7010&author=G.+Niuauthor=T.+Bowmanauthor=M.+Huangauthor=S.+Shiversauthor=D.+Reintgenauthor=A.+Daudauthor=A.+Changauthor=A.+Krakerauthor=R.+Joveauthor=H.+Yu&title=Roles+of+activated+Src+and+Stat3+signaling+in+melanoma+tumor+cell+growth&doi=10.1038%2Fsj.onc.1205859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span></div><div class="casAuthors">Niu, Guilian; Bowman, Tammy; Huang, Mei; Shivers, Steve; Reintgen, Douglas; Daud, Adil; Chang, Alfred; Kraker, Alan; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">7001-7010</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases.  Moreover, a crit. role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers.  However, the oncogenic signaling pathways in melanoma cells remain to be fully defined.  In this study, the authors demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examd.  Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines.  Consistent with a role of Src in the pathogenesis of melanoma, the authors show that c-Src tyrosine kinase is activated in melanoma cell lines.  Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited.  Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the anti-apoptotic genes, Bcl-xL and Mcl-1.  These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO46ilXC4-MLVg90H21EOLACvtfcHk0ljoDU5tehWjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D&md5=6d5f9f43c4ee07a1c2534165dd28fede</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205859%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DBowman%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DShivers%26aufirst%3DS.%26aulast%3DReintgen%26aufirst%3DD.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DRoles%2520of%2520activated%2520Src%2520and%2520Stat3%2520signaling%2520in%2520melanoma%2520tumor%2520cell%2520growth%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D7001%26epage%3D7010%26doi%3D10.1038%2Fsj.onc.1205859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span> <span> </span><span class="NLM_article-title">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1016/S0022-5347(05)64741-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2FS0022-5347%2805%2964741-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=12131365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2002&pages=762-765&author=A.+Horiguchiauthor=M.+Oyaauthor=T.+Shimadaauthor=A.+Uchidaauthor=K.+Marumoauthor=M.+Murai&title=Activation+of+signal+transducer+and+activator+of+transcription+3+in+renal+cell+carcinoma%3A+a+study+of+incidence+and+its+association+with+pathological+features+and+clinical+outcome&doi=10.1016%2FS0022-5347%2805%2964741-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span></div><div class="casAuthors">Horiguchi, Akio; Oya, Mototsugu; Shimada, Tetsuya; Uchida, Atsushi; Marumo, Ken; Murai, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-765</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: Signal transducer and activator of transcription 3 (STAT3) is known to have an important role in cytokine and growth factor signaling pathways.  In various types of human malignant tumors STAT3 has been shown to be constitutively activated due to aberrant prodn. of cytokines and growth factors.  The authors examd. the presence of STAT3 activation and its assocn. with pathol. features and clin. outcome in renal cell carcinoma cases.  Materials and Methods: the authors examd. 48 paraffin embedded renal cell carcinoma specimens and corresponding nonneoplastic kidney tissues for the activation status of STAT3 on immunohistochem. using anti-phospho-specific (p)-STAT3 antibody, which recognizes only activated STAT3.  Based on the percent of cells with pos. nuclear staining the activation status of STAT3 was detd. and categorized into 2 groups, including low - less than 10% and high - 90% or more tumor cells pos.  The assocns. of the activation status of STAT3 with pathol. features and clin. outcome were analyzed.  Results: Of 48 tumors 24 (50%) demonstrated high levels of nuclear immunostaining for p-STAT3, while the other 24 (50%) showed low levels.  Adjacent nonneoplastic kidney tissues showed only little immunostaining for p-STAT3.  A significant assocn. of high levels of p-STAT3 with metastasis was obsd.  No significant assocns. of p-STAT3 immunostaining with pathol. stage or grade were obsd.  A high level of p-STAT3 was a significant indicator of a poor prognosis on univariate and multivariate anal.  Conclusions: the authors' results indicate a high frequency of STAT3 activation in renal cell carcinoma, esp. in metastatic disease.  STAT3 activation was an independent prognostic variable in renal cell carcinoma cases.  The authors' results strongly suggest that the activation of STAT3 contributes to the development and progression of renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBk-RaURU1VLVg90H21EOLACvtfcHk0ljoDU5tehWjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D&md5=a8e5fe3f02f14b11202b78d40a42945b</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2805%2964741-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252805%252964741-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DOya%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DA.%26aulast%3DMarumo%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DM.%26atitle%3DActivation%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520in%2520renal%2520cell%2520carcinoma%253A%2520a%2520study%2520of%2520incidence%2520and%2520its%2520association%2520with%2520pathological%2520features%2520and%2520clinical%2520outcome%26jtitle%3DJ.%2520Urol.%26date%3D2002%26volume%3D168%26spage%3D762%26epage%3D765%26doi%3D10.1016%2FS0022-5347%2805%2964741-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fsj.onc.1205152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11850821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=1038-1047&author=A.+Zamoauthor=R.+Chiarleauthor=R.+Pivaauthor=J.+Howesauthor=Y.+Fanauthor=M.+Chilosiauthor=D.+E.+Levyauthor=G.+Inghirami&title=Anaplastic+lymphoma+kinase+%28ALK%29+activates+Stat3+and+protects+hematopoietic+cells+from+cell+death&doi=10.1038%2Fsj.onc.1205152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span></div><div class="casAuthors">Zamo, Alberto; Chiarle, Roberto; Piva, Roberto; Howes, Jennifer; Fan, Yan; Chilosi, Marco; Levy, David E.; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1038-1047</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in anaplastic large cell lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity.  We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs.  Furthermore, immunohistochem. studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely assocd. with ALK expression.  NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro.  Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK.  To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-xL and its role in cell survival in NPM-ALK pos. cells.  NPM-ALK expression caused enhanced Bcl-xL transcription, largely mediated by Stat3.  Increased expression of Bcl-xL provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase.  These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK pos. tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogI4o98Agys7Vg90H21EOLACvtfcHk0ljoDU5tehWjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D&md5=c7b2e63cc7765563b6d30aa4bda2569f</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205152%26sid%3Dliteratum%253Aachs%26aulast%3DZamo%26aufirst%3DA.%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DHowes%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DChilosi%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520activates%2520Stat3%2520and%2520protects%2520hematopoietic%2520cells%2520from%2520cell%2520death%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D1038%26epage%3D1047%26doi%3D10.1038%2Fsj.onc.1205152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Corvinus, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsareva, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfitzner, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L. a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beug, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhlschläger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbhuber, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, K.</span></span> <span> </span><span class="NLM_article-title">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1593/neo.04571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1593%2Fneo.04571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=16036105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=545-555&author=F.+M.+Corvinusauthor=C.+Orthauthor=R.+Morigglauthor=S.+T.+Tsarevaauthor=S.+Wagnerauthor=E.+B.+Pfitznerauthor=D.+Bausauthor=R.+Kaufmanauthor=L.+a.+Huberauthor=K.+Zatloukalauthor=H.+Beugauthor=P.+%C3%96hlschl%C3%A4gerauthor=A.+Sch%C3%BCtzauthor=K.-J.+Halbhuberauthor=K.+Friedrich&title=Persistent+STAT3+activation+in+colon+cancer+is+associated+with+enhanced+cell+proliferation+and+tumor+growth&doi=10.1593%2Fneo.04571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10fR"><div class="casContent"><span class="casTitleNuber">10f</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span></div><div class="casAuthors">Corvinus, Florian M.; Orth, Carina; Moriggl, Richard; Tsareva, Svetlana A.; Wagner, Stefan; Pfitzner, Edith B.; Baus, Daniela; Kaufmann, Roland; Huber, Lukas A.; Zatloukal, Kurt; Beug, Hartmut; Oehlschlaeger, Peter; Schuetz, Alexander; Halbhuber, Karl-Juergen; Friedrich, Karlheinz</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries.  It has so far been molecularly defined mainly by alterations of the Wnt pathway.  We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC.  Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium.  Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture.  However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation.  STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-neg. variant impaired IL-6-driven proliferation.  Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplNySx1-IGqLVg90H21EOLACvtfcHk0liCnOROoCCoqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D&md5=6d74cb8a99173e589ceee0b54c7bd487</span></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1593%2Fneo.04571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.04571%26sid%3Dliteratum%253Aachs%26aulast%3DCorvinus%26aufirst%3DF.%2BM.%26aulast%3DOrth%26aufirst%3DC.%26aulast%3DMoriggl%26aufirst%3DR.%26aulast%3DTsareva%26aufirst%3DS.%2BT.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DPfitzner%26aufirst%3DE.%2BB.%26aulast%3DBaus%26aufirst%3DD.%26aulast%3DKaufman%26aufirst%3DR.%26aulast%3DHuber%26aufirst%3DL.%2Ba.%26aulast%3DZatloukal%26aufirst%3DK.%26aulast%3DBeug%26aufirst%3DH.%26aulast%3D%25C3%2596hlschl%25C3%25A4ger%26aufirst%3DP.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DA.%26aulast%3DHalbhuber%26aufirst%3DK.-J.%26aulast%3DFriedrich%26aufirst%3DK.%26atitle%3DPersistent%2520STAT3%2520activation%2520in%2520colon%2520cancer%2520is%2520associated%2520with%2520enhanced%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D545%26epage%3D555%26doi%3D10.1593%2Fneo.04571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, Y. L.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1002/path.2041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1002%2Fpath.2041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=16917804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2006&pages=224-233&author=K.+C.+Changauthor=M.+H.+Wuauthor=D.+Jonesauthor=F.+F.+Chenauthor=Y.+L.+Tseng&title=Activation+of+STAT3+in+thymic+epithelial+tumours+correlates+with+tumour+type+and+clinical+behaviour&doi=10.1002%2Fpath.2041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10gR"><div class="casContent"><span class="casTitleNuber">10g</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span></div><div class="casAuthors">Chang, K.-C.; Wu, M.-H.; Jones, D.; Chen, F.-F.; Tseng, Y.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-233</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The STAT3 (signal transducers and activators of transcription 3) signalling pathway plays a pivotal role in oncogenesis and appears essential for postnatal maintenance of thymic architecture and thymocyte survival.  The assocn. of STAT3 activation with thymic epithelial tumors (TETs) and myasthenia gravis (MG) has not been elucidated.  In this study, 118 cases of TET and 25 non-neoplastic thymic tissue samples were evaluated for STAT3 and phospho-STAT3 (pSTAT3) expression immunohistochem.  In addn., 44 normal thymuses of different ages were included for comparison.  It was found that STAT3 activation in thymic epithelial cells (TECs), as evidenced by pSTAT3 expression and/or nuclear STAT3, was present in the majority of non-neoplastic thymuses (88%, 22/25), including those from young children, but not in fetal thymus.  In thymoma (n = 73), activated STAT3 was noted at a significantly higher frequency in the cases of lymphocyte-rich thymoma (ie types AB, B1, and B2, 46%, 23/50) in comparison with lymphocyte-depleted thymoma (types A and B3, 1/23) (p = 0.009).  Thymoma with activated STAT3 tended to present at an earlier stage, show complete resectability and less aggressive behavior, and have a higher correlation with MG than the STAT3-neg./inactive group (p < 0.05).  In contrast, thymic carcinoma with activated STAT3 (14/45, 31%) had significantly higher rates of unresectability, vascular invasion, and regional lymph node metastasis (p < 0.05).  These data provide the first evidence that constitutive STAT3 activation is seen in both benign and neoplastic thymic tissue and is assocd. with the persistence of thymic tissue and the presence of MG.  It is likely to be induced by different factors in thymoma and thymic carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGt8X77mhe7Vg90H21EOLACvtfcHk0liCnOROoCCoqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI&md5=e3966221dfbda9697a2913b34fa8d1cb</span></div><a href="/servlet/linkout?suffix=cit10g&amp;dbid=16384&amp;doi=10.1002%2Fpath.2041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2041%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DF.%2BF.%26aulast%3DTseng%26aufirst%3DY.%2BL.%26atitle%3DActivation%2520of%2520STAT3%2520in%2520thymic%2520epithelial%2520tumours%2520correlates%2520with%2520tumour%2520type%2520and%2520clinical%2520behaviour%26jtitle%3DJ.%2520Pathol.%26date%3D2006%26volume%3D210%26spage%3D224%26epage%3D233%26doi%3D10.1002%2Fpath.2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 affects melanoma on multiple fronts</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1007/s10555-005-1580-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1007%2Fs10555-005-1580-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=15986140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=315-327&author=M.+Kortylewskiauthor=R.+Joveauthor=H.+Yu&title=Targeting+STAT3+affects+melanoma+on+multiple+fronts&doi=10.1007%2Fs10555-005-1580-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10hR"><div class="casContent"><span class="casTitleNuber">10h</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 affects melanoma on multiple fronts</span></div><div class="casAuthors">Kortylewski, Marcin; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-327</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  As a point of convergence for numerous oncogenic signaling pathways, STAT3 is constitutively-activated at 50 to 90% frequency in diverse human cancers, including melanoma.  A crit. role of STAT3 in tumor cell survival, proliferation, angiogenesis, metastasis and immune evasion has been recently demonstrated.  STAT3 contributes to tumor cell growth by regulating the expression of genes that are involved in cell survival and proliferation.  STAT3 promotes metastasis and angiogenesis by inducing expression of the metastatic gene, MMP-2, and the potent angiogenic gene, VEGF.  STAT3 participates in the regulation of tumor immune evasion by inhibiting expression of proinflammatory mediators while promoting expression of immune-suppressing factors, which in turn activates STAT3 signaling in dendritic cells leading to immune tolerance.  Thus, targeting STAT3 for therapy assaults cancer on multiple fronts.  Many of the studies that defined STAT3's role in oncogenesis were carried out in melanoma cells and tumor models.  In this review, we summarize the key role of STAT3 in cancer in general and melanoma in particular.  With the emergence of small-mol. drugs that directly inhibit STAT3 or the oncogenic signaling pathways upstream of STAT3 in melanoma, a promising novel approach for melanoma therapy is emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVSFnD9ExaqLVg90H21EOLACvtfcHk0liCnOROoCCoqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D&md5=9c3739bf82951bb2f9da6a08ed08e15a</span></div><a href="/servlet/linkout?suffix=cit10h&amp;dbid=16384&amp;doi=10.1007%2Fs10555-005-1580-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-005-1580-1%26sid%3Dliteratum%253Aachs%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DTargeting%2520STAT3%2520affects%2520melanoma%2520on%2520multiple%2520fronts%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2005%26volume%3D24%26spage%3D315%26epage%3D327%26doi%3D10.1007%2Fs10555-005-1580-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidler, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danson, S. J.</span></span> <span> </span><span class="NLM_article-title">The role fo JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1038%2Fbjc.2015.233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=26151455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=365-371&author=S.+J.+Thomasauthor=J.+A.+Snowdenauthor=M.+P.+Zeidlerauthor=S.+J.+Danson&title=The+role+fo+JAK%2FSTAT+signalling+in+the+pathogenesis%2C+prognosis+and+treatment+of+solid+tumours&doi=10.1038%2Fbjc.2015.233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumors</span></div><div class="casAuthors">Thomas, S. J.; Snowden, J. A.; Zeidler, M. P.; Danson, S. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-371</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells.  Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed.  The JAK/STAT signalling pathway provides an example of this paradigm in haematol. malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clin. effective JAK2 inhibitors, such as ruxolitinib.  It is now clear that many solid tumors also show activation of JAK/STAT signalling.  In this review, we focus on the role of JAK/STAT signalling in solid tumors, examg. the mol. mechanisms that cause inappropriate pathway activation and their cellular consequences.  We also discuss the degree to which activated JAK/STAT signalling contributes to oncogenesis.  Studies showing the effect of activation of JAK/STAT signalling upon prognosis in several tumor types are summarized.  Finally, we discuss the prospects for treating solid tumors using strategies targeting JAK/STAT signalling, including what can be learned from haematol. malignancies and the extent to which results in solid tumors might be expected to differ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZLyuJNOfIZrVg90H21EOLACvtfcHk0ljA13iMJRkqYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ&md5=d9c42818af6713ce510fea404982968e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.233%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BJ.%26aulast%3DSnowden%26aufirst%3DJ.%2BA.%26aulast%3DZeidler%26aufirst%3DM.%2BP.%26aulast%3DDanson%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520role%2520fo%2520JAK%252FSTAT%2520signalling%2520in%2520the%2520pathogenesis%252C%2520prognosis%2520and%2520treatment%2520of%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D365%26epage%3D371%26doi%3D10.1038%2Fbjc.2015.233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putoczki, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylli, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luwor, R. B.</span></span> <span> </span><span class="NLM_article-title">The role of STAT3 signaling in mediating tumour resistance to cancer therapy</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1353</span>, <span class="refDoi"> DOI: 10.2174/1389450115666141120104146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.2174%2F1389450115666141120104146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=25410411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1341-1353&author=F.+H.+Tanauthor=T.+L.+Putoczkiauthor=S.+S.+Stylliauthor=R.+B.+Luwor&title=The+role+of+STAT3+signaling+in+mediating+tumour+resistance+to+cancer+therapy&doi=10.2174%2F1389450115666141120104146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy</span></div><div class="casAuthors">Tan, Fiona H.; Putoczki, Tracy L.; Stylli, Stanley S.; Luwor, Rodney B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1341-1353</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) is activated in many cancer types and can regulate pathways involving tumorigenesis, cell proliferation, cell survival and angiogenesis.  Upstream cytokine signaling through multiple trans-membrane receptors can enhance the activation of STAT3 and promote tumor progression.  Importantly, STAT3 activation can also be induced via the Janus-activated kinase 1/2 (JAK1/2) and Src family kinases.  Target-specific drug therapies have been developed to inhibit many of the upstream receptor and non-receptor activators of STAT3 and are now approved for clin. use.  Recently, resistance to std.-of-care therapies has been linked to constitutive or unabated STAT3 activation, suggesting that combination therapy with STAT3 inhibitors may be of clin. benefit.  Furthermore, STAT3 activity has also been shown to regulate self-renewal of cancer stem cells that are often refractory to chemotherapy treatment.  This review will focus on STAT3 mediated resistance to cancer therapy and discuss strategies to overcome this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFqm_bChG9_7Vg90H21EOLACvtfcHk0ljA13iMJRkqYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWltrw%253D&md5=fe787b8f33eaa8fd88f4b64fa05913e2</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.2174%2F1389450115666141120104146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450115666141120104146%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DF.%2BH.%26aulast%3DPutoczki%26aufirst%3DT.%2BL.%26aulast%3DStylli%26aufirst%3DS.%2BS.%26aulast%3DLuwor%26aufirst%3DR.%2BB.%26atitle%3DThe%2520role%2520of%2520STAT3%2520signaling%2520in%2520mediating%2520tumour%2520resistance%2520to%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2014%26volume%3D15%26spage%3D1341%26epage%3D1353%26doi%3D10.2174%2F1389450115666141120104146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of STAT3 expression and its correlation with chemioresistance of non-small cell lung cancer cells</span>. <i>Acta Histochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.acthis.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.acthis.2011.04.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2012&pages=151-158&author=Z.+Yinauthor=Y.+Zhangauthor=Y.+Liauthor=T.+Lvauthor=J.+Liuauthor=X.+Wang&title=Prognostic+significance+of+STAT3+expression+and+its+correlation+with+chemioresistance+of+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.acthis.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.acthis.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acthis.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DPrognostic%2520significance%2520of%2520STAT3%2520expression%2520and%2520its%2520correlation%2520with%2520chemioresistance%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DActa%2520Histochem.%26date%3D2012%26volume%3D114%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.acthis.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J. F.</span></span> <span> </span><span class="NLM_article-title">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3846</span>– <span class="NLM_lpage">3856</span>, <span class="refDoi"> DOI: 10.1172/JCI31871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1172%2FJCI31871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=18060032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=3846-3856&author=S.+P.+Gaoauthor=K.+G.+Markauthor=K.+Leslieauthor=W.+Paoauthor=N.+Motoiauthor=W.+L.+Geraldauthor=W.+D.+Travisauthor=W.+Bornmannauthor=D.+Veachauthor=B.+Clarksonauthor=J.+F.+Bromberg&title=Mutations+in+the+EGFR+kinase+domain+mediate+STAT3+activation+via+IL-6+production+in+human+lung+adenocarcinomas&doi=10.1172%2FJCI31871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span></div><div class="casAuthors">Gao, Sizhi Paul; Mark, Kavin G.; Leslie, Kenneth; Pao, William; Motoi, Noriko; Gerald, William L.; Travis, William D.; Bornmann, William; Veach, Darren; Clarkson, Bayard; Bromberg, Jacqueline F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3846-3856</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas.  PSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR.  Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis.  Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels.  In addn., redn. of IL-6 levels by RNA interference led to a decrease in tumorigenesis.  Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade.  Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased prodn. and release of IL-6.  Finally, immunohistochem. anal. revealed a pos. correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas.  Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-fCYAz8G9S7Vg90H21EOLACvtfcHk0ljA13iMJRkqYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO&md5=4043bc2cf3aecbfbfb3fbd8bf99d6aef</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1172%2FJCI31871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31871%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%2BP.%26aulast%3DMark%26aufirst%3DK.%2BG.%26aulast%3DLeslie%26aufirst%3DK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DGerald%26aufirst%3DW.%2BL.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DBromberg%26aufirst%3DJ.%2BF.%26atitle%3DMutations%2520in%2520the%2520EGFR%2520kinase%2520domain%2520mediate%2520STAT3%2520activation%2520via%2520IL-6%2520production%2520in%2520human%2520lung%2520adenocarcinomas%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D3846%26epage%3D3856%26doi%3D10.1172%2FJCI31871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">JAK1–STAT1–STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1083/jcb.200703184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1083%2Fjcb.200703184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2007&pages=129-138&author=L.+Sunauthor=K.+Maauthor=H.+Wangauthor=F.+Xiaoauthor=Y.+Gaoauthor=W.+Zhangauthor=K.+Wangauthor=X.+Gaoauthor=N.+Ipauthor=Z.+Wu&title=JAK1%E2%80%93STAT1%E2%80%93STAT3%2C+a+key+pathway+promoting+proliferation+and+preventing+premature+differentiation+of+myoblasts&doi=10.1083%2Fjcb.200703184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200703184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200703184%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DIp%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DJAK1%25E2%2580%2593STAT1%25E2%2580%2593STAT3%252C%2520a%2520key%2520pathway%2520promoting%2520proliferation%2520and%2520preventing%2520premature%2520differentiation%2520of%2520myoblasts%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D179%26spage%3D129%26epage%3D138%26doi%3D10.1083%2Fjcb.200703184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, H.</span>; <span class="NLM_string-name">Kubota, Y.</span>; <span class="NLM_string-name">Sato, T.</span>; <span class="NLM_string-name">Arahira, M.</span></span> Patent Appl. <span class="NLM_patent">EP 694538 1996</span>;  <i>Chem. Abstr.</i> <span class="NLM_year">1996</span>,  <span class="NLM_volume">124</span>,  <span class="NLM_fpage">289562</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=H.+Kanno&author=Y.+Kubota&author=T.+Sato&author=M.+Arahira&title=Chem.+Abstr."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKanno%26aufirst%3DH.%26jtitle%3DChem.%2520Abstr.%26date%3D1996%26volume%3D124%26spage%3D289562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortlock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2008.04.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2776-2780&author=C.+Bardelleauthor=D.+Crossauthor=S.+Davenportauthor=J.+G.+Kettleauthor=E.+J.+Koauthor=A.+G.+Leachauthor=A.+Mortlockauthor=J.+Readauthor=N.+J.+Robertsauthor=P.+Robinsauthor=E.+J.+Williams&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+1%3A+structure-based+design+and+optimization+of+a+series+of+2%2C4-bis-anilinopyrimidines&doi=10.1016%2Fj.bmcl.2008.04.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDavenport%26aufirst%3DS.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMortlock%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DRobins%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25201%253A%2520structure-based%2520design%2520and%2520optimization%2520of%2520a%2520series%2520of%25202%252C4-bis-anilinopyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2776%26epage%3D2780%26doi%3D10.1016%2Fj.bmcl.2008.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortlock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimization of 3,5-bis substituted anilinopyrimidines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5717</span>– <span class="NLM_lpage">5721</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2008.09.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5717-5721&author=C.+Bardelleauthor=D.+Crossauthor=S.+Davenportauthor=J.+G.+Kettleauthor=E.+J.+Koauthor=A.+G.+Leachauthor=A.+Mortlockauthor=J.+Readauthor=N.+J.+Robertsauthor=P.+Robinsauthor=E.+J.+Williams&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+2%3A+structure-based+discovery+and+optimization+of+3%2C5-bis+substituted+anilinopyrimidines&doi=10.1016%2Fj.bmcl.2008.09.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.087%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDavenport%26aufirst%3DS.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DMortlock%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DRobins%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25202%253A%2520structure-based%2520discovery%2520and%2520optimization%2520of%25203%252C5-bis%2520substituted%2520anilinopyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5717%26epage%3D5721%26doi%3D10.1016%2Fj.bmcl.2008.09.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van
der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6242</span>– <span class="NLM_lpage">6245</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.08.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2010.08.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6242-6245&author=C.+Bardelleauthor=B.+Barlaamauthor=N.+Brooksauthor=T.+Colemanauthor=D.+Crossauthor=R.+Ducrayauthor=I.+Greenauthor=C.+Lambert-van%0Ader+Bremptauthor=A.+Olivierauthor=J.+Read&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+3%3A+identification+of+non-benzodioxole-based+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.08.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.08.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.08.100%26sid%3Dliteratum%253Aachs%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DBrooks%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DRead%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25203%253A%2520identification%2520of%2520non-benzodioxole-based%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6242%26epage%3D6245%26doi%3D10.1016%2Fj.bmcl.2010.08.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the tyrosine kinase EphB4. Part 4: discovery and optimization of a benzylic alcohol series</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2207</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1016%2Fj.bmcl.2011.03.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2207-2211&author=B.+Barlaamauthor=R.+Ducrayauthor=C.+Lambert-van+der+Bremptauthor=P.+Pl%C3%A9author=C.+Bardelleauthor=N.+Brooksauthor=T.+Colemanauthor=D.+Crossauthor=J.+G.+Kettleauthor=J.+Read&title=Inhibitors+of+the+tyrosine+kinase+EphB4.+Part+4%3A+discovery+and+optimization+of+a+benzylic+alcohol+series&doi=10.1016%2Fj.bmcl.2011.03.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DBardelle%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DRead%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520the%2520tyrosine%2520kinase%2520EphB4.%2520Part%25204%253A%2520discovery%2520and%2520optimization%2520of%2520a%2520benzylic%2520alcohol%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2207%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2011.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, E. G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span> <span> </span><span class="NLM_article-title">Identification of the cytochrome P450 enzymes involved in the <i>N</i>-demethylation of sildenafil</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.2001.00318.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1046%2Fj.1365-2125.2001.00318.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=11298070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVOntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2001&pages=239-248&author=R.+Hylandauthor=E.+G.+H.+Roeauthor=B.+C.+Jonesauthor=D.+A.+Smith&title=Identification+of+the+cytochrome+P450+enzymes+involved+in+the+N-demethylation+of+sildenafil&doi=10.1046%2Fj.1365-2125.2001.00318.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil</span></div><div class="casAuthors">Hyland, R.; Roe, E. G. H.; Jones, B. C.; Smith, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-248</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: To characterize the cytochrome P 450 (CYP) enzymes responsible for the N-demethylation of sildenafil to its main metabolite, UK-103 320, to investigate the potential inhibitory effects of sildenafil on CYP enzymes and to evaluate the potential of selected drugs to affect sildenafil metab.  Methods: The metabolic pathways of sildenafil N-demethylation were studied using human liver microsomes, as well as microsomes expressing individual human CYP enzymes.  Further studies to identify the individual enzymes were performed at 2.5 and 250 μM sildenafil, and employed a combination of chem. inhibition, correlation anal., and metab. by expressed recombinant CYP enzymes.  In addn., the effect of sildenafil on the activity of the six major drug metabolizing enzymes was investigated.  Results: Sildenafil conversion was mediated by at least two CYP enzymes, for which the mean kinetic parameters were Km1 = 6(±3 μM), Km2 = 81(±45 μM), Vmax1=22(±9 pmol) and Vmax2=138(±77 pmol) UK-103 320 formed min-1 mg-1.  At 250 μM sildenafil, N-demethylation was primarily mediated through the low-affinity, high-Km enzyme (approx. 83%), while at 2.5 μM there was a greater role for the high-affinity, low-Km enzyme (approx. 61%).  Ketoconazole strongly inhibited metab. at both sildenafil concns. and was the only significant inhibitor at 250 μM sildenafil.  At the lower sildenafil concn., sulfaphenazole and quinidine also inhibited formation of UK-103 320.  Overall, 75% or more of the N-demethylation of sildenafil at any concn. is probably attributable to CYP3A4.  These results were supported by expts. using expressed human CYP enzymes, in which only CYP3A4 and CYP2C9 exhibited substantial sildenafil N-demethylase activity (resp. Km values of 221 μM and 27 μM).  Sildenafil metab. was inhibited by potent CYP3A4 inhibitors which are used clin., but was only a weak inhibitor of drug metabolizing enzymes itself, the strongest inhibition occurring against CYP2C9 (Ki=80 μM).  Conclusions: Evidence is provided for CYP3A4 and to a lesser extent CYP2C9-mediated metab. of sildenafil.  There is the possibility that elevated plasma concns. of sildenafil could occur with coadministration of known inhibitors of CYP2C9 or CYP3A4.  Since peak plasma concns. of clin. doses of sildenafil are only 200 ng ml-1 (∼0.4 μM) it is very unlikely that sildenafil will significantly alter the plasma concn. of other compds. metabolized by cytochrome P 450 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C2TltSf-zbVg90H21EOLACvtfcHk0lj9MB0L-Zq-0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVOntbo%253D&md5=ec1ef78013414aeba31c102e6e7ffeae</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2001.00318.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2001.00318.x%26sid%3Dliteratum%253Aachs%26aulast%3DHyland%26aufirst%3DR.%26aulast%3DRoe%26aufirst%3DE.%2BG.%2BH.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26atitle%3DIdentification%2520of%2520the%2520cytochrome%2520P450%2520enzymes%2520involved%2520in%2520the%2520N-demethylation%2520of%2520sildenafil%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2001%26volume%3D51%26spage%3D239%26epage%3D248%26doi%3D10.1046%2Fj.1365-2125.2001.00318.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1023/A:1012188625088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1023%2FA%3A1012188625088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=9165525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=568-571&author=K.+Palmauthor=P.+Stenbergauthor=K.+Luthmanauthor=P.+Artursson&title=Polar+molecular+surface+properties+predict+the+intestinal+absorption+of+drugs+in+humans&doi=10.1023%2FA%3A1012188625088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span></div><div class="casAuthors">Palm, Katrin; Stenberg, Patric; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum</span>)
        </div><div class="casAbstract">A theor. method was devised for prediction of drug absorption after oral administration to humans.  Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated.  The compds. also displayed diversity in physicochem. properties such as lipophilicity, hydrogen bonding potential and mol. size.  The dynamic mol. surface properties of the compds. were calcd., taking into account their 3-dimensional shape and flexibility.  An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar mol. surface area (PSAd) (r2 = 0.94).  The relationship was stronger than those obtained for more established predictors of drug absorption.  Drugs that are completely absorbed (FA > 90%) had a PSAd ≤ 60 Å2 while drugs that are < 10% absorbed had a PSAd ≥ 140 Å2.  PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW66hupHIyLVg90H21EOLACvtfcHk0lj9MB0L-Zq-0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D&md5=1394f0d1059e7d99ee02be977b92da8b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012188625088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012188625088%26sid%3Dliteratum%253Aachs%26aulast%3DPalm%26aufirst%3DK.%26aulast%3DStenberg%26aufirst%3DP.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DPolar%2520molecular%2520surface%2520properties%2520predict%2520the%2520intestinal%2520absorption%2520of%2520drugs%2520in%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D568%26epage%3D571%26doi%3D10.1023%2FA%3A1012188625088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lj8oFmFjCC88w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohoon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, T. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silkworth, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labowsky, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozhansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacohen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">452</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1158%2F2159-8290.CD-13-0646" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=452&author=Z.+Zhuauthor=A.+R.+Arefauthor=T.+J.+Cohoonauthor=T.+U.+Barbieauthor=Y.+Imamuraauthor=S.+Yangauthor=S.+E.+Moodyauthor=R.+R.+Shenauthor=A.+C.+Schinzelauthor=T.+C.+Thaiauthor=J.+B.+Reibelauthor=P.+Tamayoauthor=J.+T.+Godfreyauthor=Z.+R.+Qianauthor=A.+N.+Pageauthor=K.+Maciagauthor=E.+M.+Chanauthor=W.+Silkworthauthor=M.+T.+Labowskyauthor=L.+Rozhanskyauthor=J.+P.+Mesirovauthor=W.+E.+Gillandersauthor=S.+Oginoauthor=N.+Hacohenauthor=S.+Gaudetauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=R.+B.+Corcoranauthor=K.-K.+Wongauthor=W.+C.+Hahnauthor=D.+A.+Barbie&title=Inhibition+of+KRAS-driven+tumorigenicity+by+interruption+of+an+autocrine+cytokine+circuit&doi=10.1158%2F2159-8290.CD-13-0646"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0646%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DCohoon%26aufirst%3DT.%2BJ.%26aulast%3DBarbie%26aufirst%3DT.%2BU.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DMoody%26aufirst%3DS.%2BE.%26aulast%3DShen%26aufirst%3DR.%2BR.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DThai%26aufirst%3DT.%2BC.%26aulast%3DReibel%26aufirst%3DJ.%2BB.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DGodfrey%26aufirst%3DJ.%2BT.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DPage%26aufirst%3DA.%2BN.%26aulast%3DMaciag%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DSilkworth%26aufirst%3DW.%26aulast%3DLabowsky%26aufirst%3DM.%2BT.%26aulast%3DRozhansky%26aufirst%3DL.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DGillanders%26aufirst%3DW.%2BE.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DHacohen%26aufirst%3DN.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520KRAS-driven%2520tumorigenicity%2520by%2520interruption%2520of%2520an%2520autocrine%2520cytokine%2520circuit%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D452%26doi%3D10.1158%2F2159-8290.CD-13-0646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span> Data for compound <b>24</b> was
previously disclosed under the name AZ-3:<span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span> <span> </span><span class="NLM_article-title">Highly selective JAK1 kinase inhibitors suppress Y705-mediated STAT3 activation in a wide range of tumor types, with reduced hematological toxicity. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; <b>2013</b> Apr 6–10; Washington, DC. Philadelphia (PA): AACR</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">931</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2013-931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;key=10.1158%2F1538-7445.AM2013-931" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=931&author=R.+Woessnerauthor=G.+Bebernitzauthor=K.+Bellauthor=R.+Cacceseauthor=N.+Johnsonauthor=J.+Kettleauthor=C.+Rivardauthor=P.+Schroederauthor=Q.+Suauthor=H.+Wangauthor=M.+Yeauthor=W.+Zhengauthor=M.+Zindaauthor=P.+Lyneauthor=M.+Vasbinderauthor=D.+Huszarauthor=C.+Chuaqui&title=Highly+selective+JAK1+kinase+inhibitors+suppress+Y705-mediated+STAT3+activation+in+a+wide+range+of+tumor+types%2C+with+reduced+hematological+toxicity.+Proceedings+of+the+104th+Annual+Meeting+of+the+American+Association+for+Cancer+Research%3B+2013+Apr+6%E2%80%9310%3B+Washington%2C+DC.+Philadelphia+%28PA%29%3A+AACR&doi=10.1158%2F1538-7445.AM2013-931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2013-931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2013-931%26sid%3Dliteratum%253Aachs%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DCaccese%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DKettle%26aufirst%3DJ.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DChuaqui%26aufirst%3DC.%26atitle%3DHighly%2520selective%2520JAK1%2520kinase%2520inhibitors%2520suppress%2520Y705-mediated%2520STAT3%2520activation%2520in%2520a%2520wide%2520range%2520of%2520tumor%2520types%252C%2520with%2520reduced%2520hematological%2520toxicity.%2520Proceedings%2520of%2520the%2520104th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%253B%25202013%2520Apr%25206%25E2%2580%259310%253B%2520Washington%252C%2520DC.%2520Philadelphia%2520%2528PA%2529%253A%2520AACR%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D931%26doi%3D10.1158%2F1538-7445.AM2013-931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ELR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ELR','PDB','6ELR'); return false;">PDB: 6ELR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i46"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00076">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26277"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00076">10.1021/acs.jmedchem.8b00076</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Protocols for the enzyme and cell assays, synthetic methods, crystallographic information, and kinase panel selectivity data for compound <b>24</b> in Table 8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_001.pdf">jm8b00076_si_001.pdf (1.1 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00076/suppl_file/jm8b00076_si_002.csv">jm8b00076_si_002.csv (1.79 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-12%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00076%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00076" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797d59dcf91955","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
